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Activation of the pituitary and
adrenal axis is essential in modifying 
the stress response in critically ill
patients. Inadequate stress response
in critically ill patients may negatively
affect outcome. In this study,
pituitary and adrenal responses were
evaluated in patients with severe
aortic stenosis, severe sepsis and
aneurysmal subarachnoid
haemorrhage. This dissertation
provides new information on acute
hormonal response in these specific
groups of critically ill patients.
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ABSTRACT
The hypothalamo-pituitary-adrenal (HPA) axis plays a major role in the modulation of stress and inflammation in
critically ill patients. HPA-axis dysfunction may negatively affect outcome. The objective of this study was to
evaluate HPA function in different critically ill patient categories and to determine if HPA dysfunction is present.
A total of 237 critically ill patients were enrolled in the study. Sixty-six patients with severe aortic stenosis
received either etomidate or propofol to induce anaesthesia, and 125 patients had severe sepsis or septic shock.
Thirty patients had acute aneurysmal subarachnoid haemorrhage (aSAH), and 16 patients who underwent
elective intracranial aneurysm surgery served as their control. The free and/or total serum cortisol response was
evaluated in all patient categories, and the insulin-like growth factor-I (IGF-I) concentrations were measured in
patients with aSAH.
In patients with severe aortic stenosis etomidate transiently depressed cortisol synthesis and thus shortly affected
the inflammatory response. However,  etomidate did not cause as mutch hypotension than propofol.  In patients
with severe sepsis, the free and total serum cortisol concentrations correlated well. The severity of aSAH did not
affect the free or total serum cortisol concentrations. The adrenocorticotropic-cortisol profile of some patients
indicated  secondary  adrenal  insufficiency  (AI)  in  the  acute  phase  of  aSAH.  Patients  with  aSAH had low IGF-I
concentrations in the acute phase of the disease.
Calculating free serum cortisol does not provide any advantages over measuring total serum cortisol in patients
with severe sepsis, septic shock. Free serum cortisol was not helpful for predicting mortality in patients with
severe sepsis or septic shock. The severity of aSAH does not affect free or total serum cortisol concentrations. In
the  acute  phase,  some patients  may have  secondary  AI.  Serum IGF-I  may contribute  to  increased  morbidity  in
patients with aSAH. Etomidate transiently decreases serum cortisol concentration. Propofol is twice as likely as
etomidate to evoke hypotension
National Library of Medicine Classification: WC 240, WG 265, WK 515, WK 550, WK 755, WK 765, WL 355
Medical Subject Headings (MeSH): Adrenocorticotropic Hormone; Adrenal Insufficiency; Aortic Valve Stenosis;
Critical Illness;Glucocorticoids; Hypopituitarism; Insulin-Like Growth Factor I; Intracranial Aneurysm/surgery
Pituitary-Adrenal System; Pituitary Gland;Pituitary Hormones; Sepsis; Subarachnoid Hemorrhage
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TIIVISTELMÄ
Aivolisäkkeen ja lisämunuaisen (HPA) toiminta on keskeinen kriittisesti sairaan potilaan stressi- ja
tulehdusvasteen säätelijä. HPA-toiminnan häiriö saattaa huonontaa potilaiden ennustetta. Tämän tutkimuksen
tarkoituksena oli selvittää HPA-toimintaa erilaisissa kriittisissä sairaustiloissa.
Tutkimusmateriaali koostui 237 tehohoitopotilaasta. Merkittävä aorttaläpän ahtauma oli 66 potilaalla ja heidän
anestesiansa aloitusta tutkittiin antamalla heille joko propofolia tai etomidaattia. Sepsis tai septinen sokki oli 125
potilaalla ja 30 potilaalla oli lukinkalvonalainen verenvuoto (SAV). SAV-potilaiden kontrollipotilasryhmänä oli 16
suunniteltuun vuotamattoman aivovaltimopullistuman (aneurysma) leikkaukseen tullutta potilasta. Kaikilta
potilasryhmiltä mitattiin seerumin vapaan ja/tai kokonaiskortisolin pitoisuus. SAV-potilailta mitattiin lisäksi
seerumin insuliinin kaltaisen kasvutekijän (IGF-I) pitoisuus.
Etomidaatti pienensi lyhytaikaisesti aorttastenoosipotilaiden kortisolipitoisuuksia ja vaikutti siten tämän
potilasryhmän tulehdusvasteeseen. Etomidaatti ei aiheuttanut yhtä paljon verenpaineen laskua kuin propofoli.
Potilailla, joilla oli vakava sepsis vapaan ja kokonaiskortisolin pitoisuudet korreloivat hyvin. SAV:n vaikeusaste ei
vaikuttanut seerumin vapaan tai kokonaiskortisolin pitoisuuksiin. Joidenkin SAV-potilaiden
adrenokortikotrooppisen hormonin ja kortisolin pitoisuudet viittasivat sekundäärisen lisämunuaisen
vajaatoimintaan. SAV-potilaiden IGF-I-pitoisuudet olivat matalia sairauden akuuttivaiheessa.
Potilailla, joilla on vakava sepsis, seerumin vapaan kortisolin laskemisesta ei ole hyötyä verrattuna seerumin
kokonaiskortisolin mittaamiselle. Vapaan kortisolin mittaaminen ei ennustanut kuolleisuutta tällä
potilasryhmällä. SAV:n vaikeusaste ei vaikuttanut vapaan tai kokonaiskortisolin pitoisuuksiin. Joillakin SAV-
potilailla saattaa esiintyä sekundääristä lisämunuaisen vajaatoimintaa. Seerumin IGF-I-pitoisuus saattaa
vaikuttaa SAV-potilaiden toipumiseen ja sairastavuuteen Etomidaatti vaikuttaa lyhytaikaisesti potilaiden
seerumin kortisolipitoisuuksiin. Propofoli aiheuttaa kaksi kertaa useammin verenpaineen laskua kuin
etomidaatti.
Luokitus: WC 240, WG 265, WK 515, WK 550, WK 755, WK 765, WL 355
Yleinen suomalainen asiasanasto: aivolisäke; aivoverenvuoto; aneurysma; aortta-ahtauma; ennusteet; kuolleisuus;
lisämunuaiset; potilaat; sairastavuus; septinen sokki; tehohoito; tulehdus; verenmyrkytys
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11 Introduction
Severe sepsis, septic shock, aneurysmal subarachnoid haemorrhage (aSAH), and aortic stenosis are devastating
diseases with high mortality rates: 29-70% mortality in severe sepsis and septic shock (Karlsson 2007; Martin
2003) and 8-67% case fatality in aSAH (Nieuwkamp 2009). Aortic stenosis is the most common acquired valve
disease, and patients with severe untreated symptomatic aortic stenosis have a life expectancy of only 1 to 3 years
(Carabello 2009). All of these patient groups require specialised intensive care with substantial resources (Angus
2001; Niskanen 2004). Prolonged intensive care may be needed, and several comorbidities may develop during
treatment (Gruber 1999; Karlsson 2007; Macmillan 2002; Zygun 2005). The activation of the stress-induced
hypothalamo-pituitary-adrenal (HPA) axis is essential for survival under these circumstances. Moreover, the
HPA axis  and inflammation  play  major  roles  in  all  of  these  diseases,  and the  modulation  of  the  inflammatory
cortisol-HPA axis may affect outcome in all of these patient groups (Annane 2000; Schneider 2007; Shann 2006).
This knowledge has encouraged studies of the use of corticoid therapy for modulating the inflammatory response
in cardiac (Halonen 2007), septic (Marik 2008), and aSAH patients (Schneider 2007).
Recent studies have suggested that the HPA axis is disturbed in sepsis and septic shock (Marik 2008, 2009), and
this imbalance in corticoid production and peripheral effects may affect morbidity and mortality. In aSAH, acute
and secondary brain insults may cause pituitary insufficiency with an incidence as high as 36% one year after the
primary bleeding (Tanriverdi 2007). These symptoms may be misleadingly interpreted as consequences of the
brain injury itself. No data exist on the acute phase of HPA function in patients with aSAH.
All patients in intensive care may need haemodynamically stable anaesthetics, such as etomidate, for procedural
sedation. Etomidate disturbs cortisol production by causing transient adrenal insufficiency (Ledingham 1983).
This  study  was  carried  out  to  study  the  effects  of  etomidate  on  haemodynamics  and  cortisol  production  in
patients  with  severe  aortic  stenosis.  Our  aim  was  to  assess  the  impact  of  free  and  total  serum  cortisol
concentration on mortality in severe sepsis and septic shock. We hypothesized that secondary AI may develop in
acute aSAH and serum insulin-like growth factor (IGF)-I concentrations may affect morbidity in aSAH patients.
Therefore, we assessed the HPA axis and serum IGF-I concentrations following aSAH and 3 months later.
22 Review of literature
2.1 Anatomy
2.1.1 Hypothalamus
The hypothalamus is part of the diencephalon, which is a central portion of the brain located around the third
ventricle. The diencephalon includes the structures known as the thalamus, hypothalamus, epithalamus, and
subthalamus (Tamraz 2006; Tortora 2000). The hypothalamus lies inferior to the thalamus and can be divided into
four major regions that include several nuclei: mamillary, tuberal, supra-optic, and pre-optic. The mamillary
region forms the posterior hypothalamus and contains the two mamillary bodies. The tuberal region is the largest
portion of the hypothalamus, containing the infundibulum, which connects the hypothalamus to the pituitary
gland.  The  supra-optic  region  is  above  the  optic  chiasma  and  forms  the  nuclei  from  which  the  tracts  to  the
posterior  pituitary  gland  extend.  The  pre-optic  region  is  located  anterior  to  the  supra-optic  region  and  is
vascularised by branches of the anterior cerebral artery and anterior communicating artery and internal carotid
artery. The posterior regions are vascularised by the posterior cerebral artery and posterior communicating artery
(Tamraz 2006). The anterior to posterior length of the hypothalamus is only roughly 10 mm.
2.1.2 Pituitary gland
The pituitary gland weighs less than 10 g and is roughly 10 mm in length. The gland is located in the sella turcica
and hypophyseal fossa at the skull  base (Fig.  1).  The optic chiasma is anterosuperior to the pituitary gland and
lateral to the cavernous sinuses surrounding the gland. Inferiorly, the venous structures are located between the
sphenoid fossa and pituitary gland (Williams 1989).
The pituitary gland is connected to the hypothalamus by the pituitary stalk, the infundibulum. The pituitary
gland can be divided into two anatomical and functionally different parts, both of which are of ectodermic origin:
the anterior pituitary gland (adenohypophysis) and the posterior pituitary gland (neurohypophysis).
3Figure 1. This T1 weighted 3T MR image shows the anatomy of the brain of a normal control individual in the
mid sagittal and coronal plane.
The anterior pituitary gland comprises approximately 75% of the total weight of the pituitary gland and consists
of the pars anterior, pars intermedia, and pars tuberalis. The anterior portion contains different cell types:
somatotrophs, thyrotrophs, gonadotrophs, lactotrophs, and corticotrophs. Blood is supplied to the anterior
pituitary gland by a complex portal system. Hypophyseal arteries, which originate from the internal carotid
artery and posterior communicating artery, form the primary plexus of the hypophyseal portal system. This
primary portal plexus is connected by hypophyseal portal veins to a secondary portal plexus at the
adenohypophysis and drains into anterior hypophyseal veins (Tortora 2000; Williams 1989). Because of the
complex anatomy and portal vessels, the pituitary gland is thought to be especially vulnerable to trauma and
other acute intracranial pathology (Dusick 2008).
The posterior gland contains the pars posterior, infundibular stem, and median eminence. The neurohypophysis
contains pituicytes and the terminal axons of neurosecretory cells that originate from the hypothalamus and
hypothalamohypophyseal tract. Blood is supplied to the neurohypophysis by the inferior hypophyseal artery, a
branch of the internal carotid artery. The capillaries form a capillary plexus of the infundibular process and drains
into the posterior hypophyseal veins (Tortora 2000; Williams 1989).
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42.1.3 Adrenal cortex
The adrenal glands are paired organs located superior to both kidneys. The left gland is usually larger than the
right gland and they are roughly 3x2 cm in size and weigh approximately 5 g. The right gland is located behind
the inferior vena cava and is abutted to the liver and kidney. The left gland is abutted to the bursa omentalis and
ventricle, and occasionally the spleen, pancreas, splenic artery, and kidney (Tortora 2000; Williams 1989).
The adrenal glands are divided into two different functional and structural parts: the adrenal cortex and the
adrenal medulla. The cortex comprises roughly 80% of the gland’s mass and originates from the mesoderm. The
adrenal cortex can be divided into three different cellular zones that secrete different hormones.
The zona glomerulosa forms the subcapsular part of the gland and secretes mineralocorticoids. The zona
fasciculata  is  the  largest  of  the  three  parts  of  the  adrenal  gland  and  secretes  glucocorticoids.  The  innermost
cellular zone is the zona reticularis and is responsible for androgen secretion (Tortora 2000; Williams 1989).
2.2 Physiology
2.2.1 Hypothalamic hormones with a special focus on GHRH, SRIF, ghrelin, and CRF
The  hypothalamus  regulates  many  essential  homeostatic  processes  in  the  body  and  is  essential  for  regulating
temperature, osmotic pressure, circadian rhythm, visceral and somatic senses, and hormonal secretion, by which
it regulates pituitary function. The hypothalamus secretes hormones either into the portal vessels of the
hypophysis or directly affects the neurohypophysis; thus, secreting hormones directly into the general circulation.
Hypophyseal growth hormone (GH) secretion is regulated by hypothalamic hormones, including growth
hormone releasing hormone (GHRH), somatotropin release-inhibiting factor (SRIF or somatostatin), ghrelin, and
other hypothalamic peptides. GHRH was discovered in 1982 when Dr. Thorner suspected that some agent might
stimulate  GH  secretion  in  his  patient  with  an  enlarged  sella  who  had  gone  through  pituitary  surgery.  The
pathological specimen did not show any evidence of a pituitary tumour, but it did exhibit somatotroph
hyperplasia (Thorner 2008). The pituitary was suspected to be stimulated by an extrinsic factor, which led to the
finding of a GHRH-secreting pancreatic tumour and the discovery of GHRH (Esch 1982; Rivier 1982). GHRH is a
44-amino-acid peptide synthesized from a larger precursor, and its half-life is approximately 50 min (Aron 2007).
GHRH stimulates GH secretion and acts as a tropic hormone for somatotrophs in the pituitary gland. This
mechanism  was  elucidated  by  measuring  GHRH  binding  sites  in  the  pituitary  gland  (Seifert  1985).  GHRH
administration rapidly increases GH secretion. The GHRH signal is transduced by  adenylate cyclase, cAMP, and
protein kinase (Anderson 2004) and causes intracellular calcium mobilization. GHRH is also essential in the
pulsatile  pattern  of  GH  secretion  (Goldenberg  2007),  but  the  role  of  GHRH,  SRIF,  and  ghrelin  is  still  not
definitively clear. GHRH is also responsible for different GH secretion patterns in women and men (Goldenberg
2007). GHRH concentration is regulated by a negative feedback system and by neural control systems, including
sleep, age, and physical or emotional stress.
5SRIF is a 14-amino-acid peptide that inhibits GH and TSH secretion and suppresses the secretion of ACTH and
prolactin (Goldenberg 2007). Five subtypes of SRIF receptors are known, of which types 2 and 5 are the main
mediators of SRIF effects (Goldenberg 2007). SRIF does not inhibit GH synthesis but suppresses the GH response
to stimuli that usually cause GH secretion, such as exercise, stress, and hypoglycaemia. However, SFIR does not
inhibit the pulsatile pattern of GH secretion and does not inhibit the nocturnal augmentation of GH, but it affects
the amplitude and interpulse levels of GH (Dimaraki 2003).
Ghrelin is a 28-amino-acid peptide hormone discovered in the stomach as an endogenous ligand for the growth
hormone secretagogue receptor (GHS-R) that stimulates GH, ACTH, and prolactin secretion (De Vriese 2008;
Kojima 1999). Ghrelin is produced in the stomach, pituitary gland, small intestine, lung, heart, pancreas, kidneys,
and  testes.  The  peptide  stimulates  food  intake  and  GH  release,  but  it  also  has  numerous  other  functions,
including effects on the reproductive system, gastric motility, cardiovascular effects, modulation of cell
proliferation, and anti-inflammatory effects. Ghrelin is as potent as GHRH in stimulating GH secretion in the
pituitary gland, and ghrelin has an additive role in GH secretion from the pituitary gland when combined with
GHRH (Goldenberg 2007; Kineman 2007).
Corticotropin-releasing hormone (CRH) is a 41-amino-acid peptide released from various tissues in the human
body.  The  main  function  of  CRH  is  the  stimulation  of  ACTH  secretion  from  the  pituitary  gland,  but  it  is  also
involved in energy metabolism and immunology (Baigent 2001; Richard 2000). CRH is also the main activator of
pituitary-adrenal stress-related glucocorticoid secretion and is essential for the behaviour and physical changes
that occur during stress (Hillhouse 2006). Two types of CRH receptors (CRH-R) are known, and they have been
found in brain structures, including the hypothalamus, pituitary gland, amygdale, and hippocampus, but also
adipose tissue, the adrenal gland, and placenta (Hillhouse 2006). CRH binds to its carrier protein, CRHBP, which
is thought to modulate the CRH response by blocking the activation of ACTH secretion from the anterior
pituitary gland (Behan 1995).
Arginine vasopressin (AVP) is also a strong stimulator of ACTH. AVP is synthesized in the paraventricular
nucleus of the hypothalamus from where it is directly released into the hypophyseal portal system. CRH and
AVP synergistically stimulate ACTH secretion, but CRH is permissive for the action of AVP (Engelmann 2004).
2.2.2 Pituitary hormones with a special focus on GH and ACTH
GH was isolated from the pituitary gland of a human cadaver more than 50 years ago (Raben 1957). GH is a 191-
amino-acid polypeptide hormone secreted by the somatotroph cells of the anterior pituitary gland under
complicated physiological control. The main hormones regulating GH secretion are GHRH and SRIF, which react
to various hormonal, metabolic, and neural factors. GH secretion is highly pulsatile, with roughly 70% of its
secretion during the night time.
After GH binds to its receptor,  GHR, it  mediates the release of IGF-1,  which is produced by the liver and other
tissues. GH acts mainly via IGF-1, a peptide that circulates in blood bound to carrier proteins, IGFBP. Only
approximately 1% of IGF-1 is free in the circulation (Brabant 2007). Because of its ability to bind proteins and
6longer half-life than GH, IGF-1 is an attractive molecule to indirectly measure GH concentrations. However, IGF-
1 concentrations are also regulated by other factors, including nutritional state and multiple hormones. Both GH
and IGF-1 negative feedback loops regulate SRIF and GHRH secretion (Mesotten 2006).
The primary function of GH is to promote growth, but it also plays numerous other roles in important functions,
including fat metabolism by increasing lipolysis; carbohydrate metabolism by affecting glucose uptake in
extrahepatic tissues and decreasing insulin sensitivity; and protein metabolism by affecting nitrogen excretion
(Aron 2007; Salvatori 2004). Many physiological factors modify GH secretion; exercise, stress, and sleep increase
its secretion, as well as hypoglycaemia and various neurotransmitters. In addition, chronic renal failure and
starvation may increase GH secretion, but it may be decreased by several hormones described above and obesity
or hypo/hyperthyroidism (Aron 2007).
ACTH is a 39-amino-acid stress hormone produced from pro-opiomelanocortin (POMC) in the anterior pituitary
lobe and is released mainly in response to hypothalamic CRH. The CRH stress response causes pituitary ACTH
secretion in 5-10 seconds (Sapolsky 2000). ACTH mainly causes cortisol secretion, but it also affects androgen and
mineralocorticoid secretion from the adrenal cortex minutes after the induction of stress.
Similar to cortisol, ACTH levels fluctuate with the highest values measured when awake. ACTH concentrations
should be determined in the morning simultaneously with serum cortisol concentrations. ACTH pulsatility is not
lost in primary adrenal insufficiency, but exogenous cortisol administration may blunt ACTH secretion (Aron
2007).  ACTH  concentrations  are  regulated  by  three  mechanisms:  1)  fast  increase  in  serum  cortisol  levels  that
result  in  fast  feedback;  2)  the  absolute  level  of  serum  cortisol  that  results  in  slower  feedback;  and  3)  ACTH
concentrations affect its own secretion.
An overview of the HPA hormones is presented in Figure 2.
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Figure 2. Hormones secreted by the hypothalamus and pituitary gland and the major factors affecting
their regulation.
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82.2.3 Cortisol
The anti-inflammatory effects of cortisol were first described in 1949 when Hench showed that cortisol has anti-
inflammatory effects in rheumatoid arthritis (Hench 1949), and new mechanisms for the actions of cortisol, such
as the differentiation of anti-inflammatory monocytes, have since been discovered (Ehrchen 2007).
Glucocorticoids are widely used because of their ability to inhibit the expression of pro-inflammatory genes (Lasa
2002). HPA activation and the resulting cortisol secretion is an essential mechanism for adapting to stress and
maintaining homeostasis. In healthy patients, cortisol secretion has a great diurnal variation that is lost in critical
illness (Cooper 2003).
The adrenal gland has small amounts of free, immediately available cortisol for secretion, and the majority of
cortisol has to be synthesized from cholesterol. ACTH induces the conversion of cholesterol to pregnenolone. The
cascade ends in 11-hydroxylation, with 11-deoxycortisol being hydroxylated to form cortisol. In humans, a mean
of 9.2 mg of cortisol is synthesized per day (Aron 2007).
Glucocorticoid  receptors  are  found in  almost  all  human cells  (Rhen 2005).  Roughly  90% of  cortisol  is  bound to
cortisol binding globulin (CBG) and albumin, and only approximately 10% of cortisol is in its free and active
form. Free cortisol is  responsible for its physiological effects.  Any alterations in the binding proteins may affect
the free serum cortisol concentrations, which might be important in critical illness (Christ-Cain 2007; Ho 2006; le
Roux 2003).
Cortisol acts via the glucocorticoid receptor to induce gene expression (Aron 2007). Because of the pleiotropic
effect of cortisol, the results of the activation of the glucocorticoid receptor may be either stimulatory or inhibitory
(Rhen 2005).
The anti-inflammatory effects of glucocorticoids are mediated by three different receptor-glucocorticoid
mechanisms: non-genomic activation, DNA-dependent activation, and protein interference regulation (Rhen
2005). The result is an inhibition of the effects of cytokines and inflammatory mediators.
Glucocorticoids induce several anti-inflammatory proteins. Annexin-I protein inhibits the formation of arachnoid
acid and prostaglandins, leukotrienes, prostacyclins, and thromboxanes by inhibiting the formation of cytosolic
phospholipase A2. Mitogen-activated protein kinase (MAPK) is activated, for example, by bacteria, viruses, and
free radicals, and this anti-inflammatory pathway inhibits the formation of phospholipases, cytokines, adhesion
molecules, and matrix metalloproteinases (Lasa 2002; Rhen 2005). Glucocorticoids also block the activation of
nuclear factor-B (NF-B), resulting in diminished formation of tumour necrosis factor (TNF)-, cytokines, and
adhesion molecules (De Bosscher 2003). Glucocorticoids also enhance the production of endothelial nitric oxide
(Hafezi-Moghadam 2002). Recent studies have suggested that glucocorticoids may have complex properties for
modifying monocytes in inflammation and diminishing tissue damage in infection (Ehrchen 2007).
Glucocorticoids improve the reactivity of catecholamines with their receptors, which was described in 1966 (Besse
1966). This feature is important in the clinical setting, for example, of septic shock. Glucocorticoids also have
several effects on many end organs. Glucocorticoids affect blood glucose levels by increasing gluconeogenesis in
hepatic cells, inducing peripheral insulin resistance, and they increase lipolysis and are catabolic by decreasing
9protein synthesis (Aron 2007). Glucocorticoids also cause bone and fibroblastic loss, affect calcium metabolism,
and inhibit growth in excess amounts.
2.3 Defining critical illness
Intensive care units (ICUs) provide care for patients with severe illness and underlying organ failure. Because of
limited resources and patient heterogeneity in ICUs, the critical illness that should be handled in an ICU
environment should be defined. For adequate resource allocation of ICU treatment, not treating patients “too well
to benefit” or “too sick to benefit” is necessary (Egol 1999). The symptoms and/or underlying disease leading to
intensive care should be temporary, and the ICU intervention should provide therapies not available elsewhere
(Egol 1999).
Critical illness is usually defined as life threatening but treatable symptoms. Certain guidelines exist for the
clinical, laboratory, and radiological findings that can be used as criteria to assess patients for intensive care (Egol
1999). Typically, such patient groups include those who are haemodynamically unstable (e.g., severe sepsis,
cardiac insufficiency), underwent major operations (e.g., cardiac surgery), have altered consciousness (e.g.,
subarachnoid haemorrhage, traumatic brain injury [TBI]), and those who have primary respiratory failure (e.g.,
pneumonia). All such critically ill patients may need ventilatory support and vasoactive therapy. Thus, any of
these patients may present multiorgan failure during their stay in the ICU.
The need for effective and ethical treatment has led to the development of general scoring systems, such as Acute
Physiology and Chronic Health Evaluation (APACHE) II and Simplified Acute Physiology Score (SAPS) (Knaus
1985; Le Gall 1984, 1993), to assess the severity of illness and predict outcome in order to better assess the
prognosis and performance of different ICUs. Also, organ specific severity scoring, such as the Sequential Organ
Failure Assessment (SOFA) (Vincent 1998), has been used to assess disease severity. Along with the general ICU
disease severity scorings, additional disease-specific scores are used. In aneurysmal subarachnoidal hemorrhage
(aSAH), the most common severity classification is the Hunt & Hess grading scale (Hunt 1968) in which the
clinical condition of the patient is divided into five different classes. An other important classification score
commonly used is the World Federation of Neurosurgical Societes (WFNS) scale (Report of…1988)  in which the
severity of aSAH is divided as well in five different classes. Moreover, the Fisher classification of blood on
computed tomography is divided into four classes (Fisher 1980). In aortic stenosis, the pre-operative aortic valve
area and/or stenosis gradient is used for these purposes, and an aortic valve area of less than 1.0 cm² and a mean
transvalvular gradient of more than 40 mmHg are considered as severe aortic stenosis (Carabello 2009). However,
assessing the clinical symptoms of these patients in addition to echocardiographic findings is essential because
severe clinical symptoms have a huge impact on mortality (Carabello 2009).
Furthermore, all of these patients are in acute, fulminate stress that activates the hypothalamo-pituitary axis to
secrete  essential  hormones  for  adapting  to  the  situation  and  have  a  risk  of  developing  HPA  insufficiency
(Vanhorebeek 2006). The mechanisms for developing HPA insufficiency may be different in the subgroups of
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different patient categories. Notably, the ICU environment predisposes patients to several drugs that may
influence the function of the HPA axis (Ambrogio 2008).
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2.3.1 Severe sepsis and septic shock
Sepsis is currently defined according the guidelines from 1992 (Bone 1992). Sepsis is described as a systemic
response to infection. Septic symptoms without infection are called systemic inflammatory response syndrome
(SIRS). Sepsis is a continuum of clinical and pathophysiological symptoms and severity degrees which have
negative impact on patient outcome. Therefore, severe sepsis and septic shock criteria have been defined. Severe
sepsis is sepsis with at least one organ dysfunction. Additionally, in septic shock, hypotension is presented
despite adequate fluid resuscitation (Table 1).
The incidence of severe sepsis varies in different studies. In a large retrospective study the incidence was 3/1000
population in the USA (Angus 2001). In Finland a recent prospective study showed an incidence of severe sepsis
of 0.38/1000 in adult population (Karlsson 2007).
Patients with severe sepsis and septic shock have high mortality rates.  In Finland, cumulative ICU, hospital,  1-
year, and 2-year mortalities are 15.5%, 28.3%, 40.9% and 44.9% (Karlsson 2007,2009).
Table 1. Definition and criteria of sepsis (Bone 1992).
Infection Microbial phenomenon characterised by an inflammatory response to the
presence of microorganisms or the invasion of normally sterile host tissue by
those organisms.
Bacteremia        The presence of viable bacteria in the blood.
Systemic inflammatory SIRS to a variety of severe clinical insults. The response is
response syndrome                      manifested by two or more of the following conditions.
(SIRS)
       1.temperature >38ºC or < 36ºC
       2.heart rate >90/min, respiratory rate >20/min, PaCO2<4.3kPa
                                3.white blood cell count > 12 x 106/mm3  or > 10% immature (band) forms
Sepsis                                             The systemic response to infection, manifested by two or more SIRS criteria.
      Severe sepsis                                 Sepsis associated with organ dysfunction, hypoperfusion or hypotension.
Hypoperfusion and perfusion abnormalities may include, but are not limited to
       lactic acidosis, oliguria, or an acute alteration in mental status.
Septic shock                                  Sepsis-induced hypotension despite adequate fluid resuscitation along with the
presence of perfusion abnormalities that may include, but are not limited to,
                                                         lactic acidosis, oliguria, or an acute alteration in mental status. Patients who are
                                                         receiving inotropic or vasopressor agents may not be hypotensive at the time that
                                                         perfusion abnormalities are measured.
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2.3.2 Aneurysmal subarachnoid haemorrhage as a systemic disease
Twenty-three  to  forty-two  percent  of  deaths  following  aSAH  are  assumed  to  be  due  to  extracerebral  organ
dysfunction (Stevens 2007). However, these figures differ substantially between studies (Schuiling 2005). Despite
aSAH is primarily affecting the brain, it has widespread systemic and extracerebral manifestations.
Cardiac dysfunction is classically thought to be due to catecholamine storm (Naredi 2000), and an imbalance
between humoral and neural function may exist (Stevens 2007). ECG changes related to acute brain catastrophes
have been known for decades; aSAH may cause ST-segment elevations or depressions, T-wave abnormalities, and
several conduction disturbances (Macrea 2005). Also, several echocardiographic changes, such as left ventricular
diastolic and systolic dysfunction, have been reported (Mayer 1999; Tung 2005). Serum CK-MB and troponin
concentrations may also be elevated (Naidech 2005; Stevens 2007). Cardiac and haemodynamic complications
have a negative impact on the outcome in patients with aSAH (Naidech 2005; Stevens 2007).
Neurogenic pulmonary oedema may occur in patients with aSAH, and it is described as pulmonary oedema with
only aSAH being the identifiable precipitating factor. More severely ill aSAH patients seem to suffer more often
from neurogenic pulmonary oedema than less severely ill patients. The overall incidence of neurogenic
pulmonary oedema is reported to have a wide variability and is reported to be 2-42% (Friedman 2003; Stevens
2007). Pneumonia, acute lung injury, and acute respiratory distress syndrome (ARDS) may also complicate the
clinical course of aSAH (Stevens 2007). Pulmonary complications are the most common non-neurological causes
of in-hospital deaths in patients with aSAH, accounting for 11% in one study (Solenski 1995).
In addition, aSAH may cause immunological and metabolic disturbances. Anaemia is common in aSAH patients
and may also have a negative impact on outcome (Kramer 2009). Furthermore, platelet dysfunction may appear
(Juvela 1991).
Fever  is  a  common  finding  in  patients  with  aSAH  that  negatively  affects  outcome  (Fernandez  2007)  and  may
reflect the pro-inflammatory state of aSAH (Stevens 2007). aSAH is well known to cause major electrolyte
disorders, such as the syndrome of inappropriate ADH secretion (SIADH) or cerebral salt wasting syndrome
(CSWS) affecting sodium balance (Kao 2009). Moreover, treatment with the electrolyte magnesium may be
beneficial in patients with aSAH (Mees 2007).
All of these non-neurological complications require attention and a multidisciplinary therapeutic approach.
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2.4 Pathophysiology of the pituitary-adrenal axis
2.4.1 Pathophysiology of the pituitary-adrenal axis in severe sepsis and septic shock
Activation of the HPA axis is essential  for survival,  and it  is  activated by several mechanisms in severe sepsis.
Glucocorticoids are essential when the vasomotor tone of the vasculature is impaired and affect the distribution
of body fluids. Glucocorticoids are also essential for sensitizing the catecholamine receptors (Rhen 2005). Serum
cortisol concentrations increase in response to stress in critical illness (Briegel 2009). However, CBG
concentrations decrease and, therefore, free serum cortisol is elevated in sepsis (Hamrahian 2004).
A  vast  amount  of  literature  has  been  published  during  the  last  years  about  sepsis  and  AI.  The  HPA  axis  and
peripheral tissues are involved in a complex manner, causing either HPA insufficiency and/or peripheral
glucocorticoid receptor insufficiency (Marik 2009). Meduri et al. (2002) showed that the affinity of glucocorticoid
receptors to glucocorticoids may be altered, and the nuclear glucocorticoid receptor activity may be especially
impaired in critically ill patients (Kino 2003; Meduri 2005).
The most potent glucocorticoid secretion activators are CRH and AVP secreted from the hypothalamus (Marik
2007, 2009). CRH and ACTH secretion is modulated by complex responses to different cytokines and interleukins.
Cytokines, such as TNF-, affect NF-B, and glucocorticoids affect transcription factors involved in cytokine gene
transcription, potentially inhibiting cytokine synthesis (Auphan 1995; Barnes 1997).
Because of the vulnerable low pressure blood supply system of the pituitary gland, these structures are
susceptible to low blood pressures. This condition was classically shown in Sheehan’s syndrome in which
cardiovascular collapse causes pituitary necrosis (Kelestimur 2003). Sharshar et al. (2004) performed a prospective
autopsy  study  in  which  they  compared  ICU  patients  who  died  due  to  septic  shock,  non-septic  shock,  and
extracranial injury. The researchers measured ischemic/haemorrhagic areas in different locations of the brain and
analysed TNF-, IL 1-, iNOS, and apoptosis. A significant increase in ischemic lesions in the hypothalamic
regions was reported in patients who died due to septic shock. Also, the apoptotic scores were higher in patients
with septic shock than in patients without sepsis. Apoptotic mechanisms are involved in brain autonomic nuclei
dysfunction and may affect CRH secretion (Sharshar 2003), which may be induced by TNF- and IL-6 (Soni 1995).
Apoptotic mechanisms play a major role in brain dysfunction, and the main stimulators of apoptosis appear to be
the inflammatory mediators and mechanisms involved in sepsis: TNF-, IL 1-, interferon-, and ischemia (Lee
2001; Yuan 2000). Moreover, the cytokines play a pivotal role in modulating the enzyme cascades responsible for
glucocorticoid uptake into cells (Marik 2009).
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2.4.2 Pathophysiology of the pituitary-adrenal axis in aneurysmal subarachnoid haemorrhage
The mechanisms behind pituitary-adrenal insufficiency in patients with aSAH have not been identified in any
clinical study. Certain types or locations of intracerebral aneurysms that could cause more pituitary deficiencies
than others have not been identified in any clinical or systematic neuropathological study. Some
pathophysiological mechanisms and cascades leading to secondary brain injury are quite similar in patients with
TBI  and  patients  with  aSAH.  Thus,  the  mechanisms  causing  general  pituitary  insufficiency  in  aSAH  may  be
similar to the mechanisms causing pituitary insufficiency in patients with TBI.
Hypopituitarism following brain trauma was reported as early as 1918 (Cyran 1918) when a patient with a
fracture of the base of the scull and pituitary damage was described. Several reports have been published since
that first description (Benvenga 2005), but the recognition of post-traumatic hypopituitarism has been poor. Since
the 1950s, some autopsy studies in which pituitary and/or hypothalamic lesions were described in patients with
fatal head injuries have been published (Daniel 1959), and the first large case series were published in 1986
(Edwards 1986) and 2000 (Benvenga 2000). The first reports of pituitary lesions in aSAH were published in 1963
(Crompton 1963). In this autopsy study, hypothalamopituitary lesions were identified in patients who died after
acute aSAH.
Crompton  et  al.  (1963)  found  that  patients  who  had  died  due  to  the  rupture  of  an  anterior  or  posterior
communicating artery had more frequent hypothalamus lesions; micro- and macrohaemorrhages, necrosis, and
ischemic  lesions  were  found  in  the  hypothalamus.  Haemorrhages  in  the  pituitary  regions  were  proposed  to
originate from obstruction of the venous drainage by increased intracranial pressure. The first patient with
hypopituitarism  to  survive  aSAH  was  described  in  1963  and  had  hypopituitarism  due  to  the  rupture  of  the
anterior communicating artery (Hoff 1961). For decades, large cerebral aneurysms have been known to cause
hypopituitarism (White 1961).
One factor causing HPA insufficiency may be direct damage of the hypothalamic/pituitary vasculature at the time
of aneurysm bleeding and/or vasoconstriction (Schneider 2007). The vulnerable anatomical location in the sella
turcica and the fragile infundibulum puts the pituitary at risk with any acute intracranial pathology, leading to
hormonal disturbances (Dusick 2008). Secondary insults, such as hypoxia, hypotension, and anaemia, may also
contribute to pituitary insufficiency in acute brain catastrophes (Dusick 2008; Schneider 2007). Inflammatory
mediators, such as cytokines, might play a role in these situations as well (Dimopoulou 2004).
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2.5 Pathophysiology of the GH-IGF-I axis in aneurysmal subarachnoid haemorrhage
GH  is  secreted  from  the  pituitary  in  a  pulsatile  manner.  In  the  acute  phase  of  critical  illness,  GH  secretion  is
increased, and the situation resembles starvation (Hartman 1992; Mesotten 2006). IGF-I concentration is low in the
acute  phase  of  critical  illness,  though  the  bioavailability  of  IGF-I  may  be  increased  due  to  changes  in  IGF-I
binding proteins (Baxter 1998; Timmins 1996). Some evidence for GH receptor resistance in septic situations has
also been reported (Defalque 1999). If critical illness is sustained, the pulsatility of GH secretion diminishes and
the total GH concentration is low.
Alterations in GH secretion are the most common pituitary deficiencies in aSAH and TBI (Aimaretti 2004;
Dimopoulou 2004). Why the GH-IGF axis is the most vulnerable pituitary hormone pathway remains unclear, but
it may be reasonable to think that the mechanism of GH deficiency in TBI is similar to the mechanism in aSAH. In
this context, the special vulnerability of the somatotrophs located in the lateral wings of the anterior pituitary
gland  may  explain  why  GH  deficiency  is  the  most  common  pituitary  deficiency  in  aSAH  (Popovic  2005).  The
actions of GH are mediated via IGF-I, a potent regulator of neuron growth (Kooijman 2006, 2009) that has
substantial effects on apoptosis. Neuronal cell death and new concepts of the mechanism of early brain injury are
important in the pathophysiology of aSAH (Cahill 2006).
2.6 Defining GH and IGF-I insufficiency, with a special focus on aneurysmal subarachnoid haemorrhage
GH and IGF-I insufficiency are diagnosed by several methods, and the method used can essentially affect the
results. Guidelines exist for diagnosing adult GH deficiency (Gasco 2008; Ghigo 2005). Generally, a provocative
test for diagnosing adult onset GH deficiency should be done (Gasco 2008; Ghigo 2005). If a GH sample is taken
during the pulsatile cycle when GH concentration is low, it does not confirm GH deficiency. The insulin tolerance
test  (ITT)  is  the  gold  standard  for  diagnosing  GH  deficiency  (Aron  2007;  Gasco  2008).  The  ITT  evokes  stress-
mediated activation of the HPA axis with increases in GH concentration. In the setting of acute aSAH, the ITT test
cannot be performed because of the risk of severe hypoglycaemia, which could be deleterious for the patient.
Furthermore, the test is contraindicated in patients with cerebrovascular or ischemic heart disease and seizure
disorders (Aron 2007; Ghigo 2005). The ITT has good specificity and sensitivity (Biller 2002). GHRH-arginine test
is as reliable in detecting GH deficiency as the ITT when adequate cut-off limits are used (Biller 2002); however, it
is contraindicated in patients with severe liver or renal disease or acidosis.
The role of single IGF-I measurements in detecting GH deficiency is controversial.  Normal IGF-I values do not
rule out pituitary GH deficiency (Gasco 2008). Patients with panhypopituitarism may even have normal IGF-I
values (Aimaretti 2003, 2004). Biller et al. (2002) showed that an IGF-I level of less than 77 μg/l may be used.
Hartman et al. (2002) found that patients with appropriate clinical history and/or other pituitary deficiencies
could be diagnosed with GH deficiency by measuring IGF-I.
Aging is a confounding factor in the assessment of IGF-I concentrations because the concentration decreases with
age (Aimaretti 2003). Insulin, stress, liver function, and nutritional status may also influence IGF-I concentrations.
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In particular, obese patients may have normal, or even high, IGF-I concentrations despite GH deficiency
(Maccario 2000).
Kelly et al. (2000) defined GH insufficiency using the ITT at least 3 months after TBI or aSAH. As a result, 18.2%
of examined individuals had GH deficiency using the ITT criteria and none were GH deficient using the IGF-I
criteria. Hypoxia, brain swelling, low initial GCS-values, and hypotension were associated with hypopituitarism.
Brandt  et  al.  (2004)  showed  that,  in  the  chronic  phase  of  aSAH,  IGF-I  levels  were  at  the  lower  limit  in  some
patients.
Dimopoulou et al. (2004) reported that, 12 to 24 months after aSAH, a morning IGF-I concentration of less than 2
standard deviations for the appropriate age range was considered to be GH deficiency; The severity or functional
outcome of aSAH did not correlate with hormonal disturbances.
Aimaretti et al. (2004, 2005) used the GHRH-arginine test to evaluate the GH-IGF-I axis in aSAH patients 3 to 12
months after ICU discharge; the incidence of GH deficiency was 25% and 2.5% using IGF-I measurements.
GH deficiency is the most common pituitary disturbance in aSAH patients at 3 months. In a follow-up study from
3 months to 1 year, Aimaretti et al. (2005) found severe GH deficiency 1 year after aSAH in 21.8% of patients and
partial GH deficiency in 15.6% of patients.
Tanriverdi et al. (2007) studied pituitary function within 24 hours of admission and at 12 months in patients with
aSAH. A GHRH test was used at 12 months. In the acute phase, 22.7% of patients were GH deficient and 36.4%
were GH deficient at 12 months. IGF-I concentrations were similar in GH deficient and sufficient patients.
Hypopituitarism was not associated with the grade of aSAH as assessed by Hunt & Hess or Fisher CT scales.
Although hypopituitarism and outcome have not been extensively studied in patients with aSAH, they are
generally associated with high morbidity and mortality (Agha 2005; Cohan 2005; Schneider 2007). Kreitscmann-
Andermaht et al. (2007) reported that low cortisol or GH deficiency may negatively affect quality of life 1 year
after aSAH.
Although IGF-I reflects the function of the pituitary-GH axis,  new aspects of its pivotal role in neuroprotection
have been revealed (Kooijman 2009). In addition to mostly experimental animal studies (Kooijman 2006, 2009),
recent studies have shown the potential role of IGF-I in protection against brain ischemia (Bondanelli 2006).
2.7 Defining ACTH and cortisol insufficiency in severe sepsis and septic shock
Both ACTH and serum cortisol secretion have a circadian rhythm (Aron 2007), which must be taken into account
when measuring serum concentrations in humans. Basal total serum cortisol concentrations should be measured
in the morning (e.g., 8-9 am) (Aron 2007) because the concentrations are highest at that time.
Both  basal  and  stimulated  serum  cortisol  concentrations  are  used  to  define  AI  in  critically  ill  patients.  Basal
concentrations are usually higher in critically ill patients compared to healthy volunteers (Hamrahian 2004).
Several cut-off limits for basal serum cortisol concentrations are used for detecting AI in critically ill patients. A
basal cortisol level of less than 165 nmol/l has been used to define absolute AI in unstressed subjects, and a serum
cortisol concentration of less than 300 nmol/l is suspicious of primary AI (Arlt 2003). In critical illness, random
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serum cortisol concentrations of less than 414 nmol/l are proposed to be indicative of AI (Cooper 2003). Marik et
al. (2003) reported that, in patients with septic shock, a basal total cortisol concentration of <690 nmol/l is a good
discriminator of AI. In the retrospective Corticus cohort study (Lipiner 2007), the baseline and stimulated cortisol
levels were compared in relation to mortality in severe sepsis and septic shock. Basal serum cortisol
concentrations  were  not  associated  with  clinical  outcome.  The  incidence  of  AI  varies  depending  on  the  cut-off
value used for AI (Bernard 2006; Lipiner 2007).
The simultaneous determination of serum ACTH and cortisol concentrations makes it possible to differentiate
between primary and secondary AI (Arlt 2003). Long lasting (>4 weeks) ACTH deficiency causes adrenal gland
atrophy and ACTH receptor down-regulation (Arlt 2003). By administering synthetic ACTH, the adrenal gland
can be induced to produce cortisol and, thus, evaluate the reserve of the gland to produce cortisol (Aron 2007).
Usually, 250 µg of synthetic ACTH analogue is administered intravenously, and the cortisol response is evaluated
by blood samples 30 and 60 minutes after administration.
In patients with severe sepsis or septic shock, the concept of relative AI was introduced in 1991 (Rothwell 1991).
Relative AI is defined as normal, or even elevated, serum cortisol that is inadequate for meeting the needs of
stress. Rothwell et al. (1991) demonstrated that patients who have a blunted response (<250 nmol/l) to stimulated
cortisol production have a worse outcome in septic shock than those with a response to the ACTH stimulation
test of >250 nmol/. Several years passed before Annane et al. (2000) confirmed that patients with septic shock are
more  likely  to  die  if  they  do  not  respond  to  exogenous  ACTH  due  to  increasing  cortisol  levels  (>248  nmol/l).
These results have been confirmed in several studies (Annane 2006; Bollaert 2003). The ACTH stimulation test is
also used to determine the need for glucocorticoid therapy. Patients with a blunted response (serum cortisol
increase of <248 nmol/l) after ACTH stimulation, in particular, would benefit from cortisol replacement therapy
(Annane 2002). Moreover, some studies demonstrated that, regarding of the response to an ACTH stimulation
test and/or simply giving low dose hydrocortisone reveals shock more rapidly (Annane 2002; Bollaert 1998;
 Briegel 1999; Oppert 2005).
In the Corticus study (Sprung 2008) a cortisol increase of less than 248 nmol/l in the ACTH stimulation test was
used to define AI. No mortality differences were detected between patients defined as having AI and those who
did not, or between patients who received hydrocortisone and those who did not. Hydrocortisone reversed shock
more quickly than not receiving hydrocortisone.
The ACTH test is not capable of detecting secondary AI because the adrenal gland response may be normal (Aron
2007;  Streeten  1996).  The  ACTH test  does  not  assess  the  integrity  of  the  HPA axis  and it  does  not  provide  any
information about the adequate amount of cortisol needed for particular stress. Moreover, timing and
reproducibility of the ACTH test has been questioned (Loisa 2005).
In  the  standard  ACTH  stimulation  test,  the  supraphysiological  amount  of  ACTH  is  used.  A  low  dose  ACTH
stimulation test is  possible by administering 1 µg of ACTH. This method has not been better than the standard
method in critically ill patients (Arafah 2006).
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Beishuizen et al.  (2001) found extremely low CBG values at the beginning of septic shock, and the free cortisol
index (cortisol/CBGx100) was high at the beginning of septic shock, reflecting high free cortisol concentrations.
After several days, the free cortisol index normalised and no impact on mortality was detected.
A  study  of  free  serum  cortisol  found  that  patients  who  were  hypoalbuminemic  had  low  total  serum  cortisol,
whereas hypoalbuminemia did not affect free serum cortisol concentrations (Hamrahian 2004). The authors
concluded  that  measuring  free  serum  cortisol  may  be  important  in  critically  ill  patients  and  recommended  a
threshold of 55.2 nmol/l free serum cortisol in patients at risk for AI. However, blood CBG concentrations also
vary among healthy individuals (Dhillo 2002). Ho et al. (2006) compared calculated and measured free serum
cortisol concentrations with total serum cortisol concentrations in patients with sepsis and septic shock. Measured
and calculated free serum cortisol correlated well. Free serum cortisol concentrations better reflected circulating
glucocorticoid activity.
In pneumonia, measuring free serum cortisol was not superior to measuring total serum cortisol (Christ-Crain
2007).  Annane  et  al.  (2006)  used  metyrapone  testing  to  detect  AI  in  patients  with  sepsis  compared  to  healthy
volunteers and found that a free serum cortisol concentration of less than 22 nmol/l predicted AI, but measuring
free serum cortisol did not have any advantages over measuring total serum cortisol. These studies led to free
serum cortisol measurements not being recommended for routine use at this time (Marik 2008). The reason for the
recommendation is the fact that the test methods are not routinely available and no normal range values are
available for critically ill patients.
In 2008, a consensus statement was developed for the diagnosis and management of corticosteroid insufficiency
in critically ill adult patients (Marik 2008). Experts recommend avoiding the description of absolute or relative AI
and critical illness-related corticosteroid insufficiency (CIRCI) should be used. Adrenal insufficiency in critical
illness should be defined as an increase of <248 nmol/l in an ACTH stimulation test or as a random total cortisol
concentration of <275 nmol/l.  An ACTH stimulation test should not be used to guide glucocorticoid therapy in
septic shock; glucocorticoid therapy should be used in patients who respond poorly to fluids and vasopressor
agents.
2.8 Defining pituitary adrenal insufficiency in aneurysmal subarachnoid haemorrhage
Subarachnoid haemorrhage may cause adrenal and/or pituitary insufficiency. Cut-off values for serum ACTH
and cortisol concentrations are mostly derived from endocrinological studies performed in healthy patients or
from patients with known pituitary deficiency (Schneider 2007). No consensus exists on the reference values for
serum cortisol or ACTH concentrations in acute neurosurgical catastrophes like aSAH (Table 2).
A preliminary study of HPA dysfunction in patients with aSAH months after the insult found that, using the ITT,
aSAH  does  not  seem  to  cause  any  ACTH  and/or  cortisol  insufficiency  (Kelly  2000).  Another  study  found  that
pituitary-adrenal function is preserved in patients with syndromes of fatigue after aSAH (Brandt 2004).
Aimaretti et al. (2004, 2005) studied the incidence of pituitary deficiency 3 and 12 months after discharge from the
ICU using multiple endocrine testing. At 3 months,  no aSAH patient presented with total hypopituitarism and
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only  one  patient  out  of  40  had secondary  AI.  In  their  follow-up study (3  months  to  1  year),  none  of  the  aSAH
patients with normal pituitary function at 3 months  developed pituitary dysfunction at 1 year. However, one of
the 32 patients had secondary AI at 3 months and two had secondary AI at 1 year. Regarding all pituitary
hormones,  patients  with  some  pituitary  deficits  at  3  months  may  develop  new  deficits  up  to  1  year.
Kreitschmann-Andermahr et al. (2003) published a short report of pituitary deficiency 12 to 60 months after aSAH
in which aSAH was shown to cause corticotropin deficiency in 29% of patients. In 2004, the same group published
a study in which 32.5% of patients with aSAH had isolated corticotroph deficiency indicated by the ITT 1 year
after bleeding (Kreitschmann-Andermahr 2004). In another study (Dimopoulou 2004), 10% of patients with aSAH
were hyporesponsive in an ACTH stimulation test 12 to 24 months after aSAH. Tanriverdi et al. (2007) studied
aSAH  patients  within  24  hours  of  admission  and  after  12  months,  finding  that  22.7%  of  patients  were  ACTH
deficient in the acute phase and 13.6% were ACTH deficient after 1 year.
To date, the only study evaluating free serum cortisol in patients with aSAH was performed by Savaridas et al.
(2004), but only six patients in the study had acute aSAH. However, the study found that the CBG concentration
declined in patients with aSAH and the free fraction of cortisol may better reflect serum cortisol concentrations.
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Table 2. A selection of studies investigating aSAH and pituitary-adrenal insufficiency (AI).
Study No. of
patients
Diagnostic test Diagnostic criteria %
having
AI
Time of
assessment
Kelly et al. 2000 2 ITT Out of 95% CI of
reference values for
healthy controls
0 Not specified
Savaridas et al.
2004
6 None Total serum cortisol
<140-690 nmol/l
Not
assessed
Within 5 days
of SAH
Brandt et al.
2004
10 ITT Not given 0% Within 4-16
months post
SAH
Aimaretti et al.
2004
40 Basal hormone
screening and
urinary cortisol
measurement
Morning total serum
cortisol <220 nmol/l,
free urinary cortisol <
83 nmol/l, and other
than cortisol deficit
2.5% 3 months after
ICU discharge
Aimaretti et al.
2005
32 Basal hormone
screening
Morning total serum
cortisol <220 nmol/l
3.1-
6.25%
3 and 12
months after
SAH
Kreitschmann-
Andermahr et
al. 2004
40 ITT Total serum cortisol <
500 nmol/l after ITT
32.5% 12-72 months
after SAH
Kreitschmann-
Andermahr et
al. 2003
21 ITT Total serum cortisol <
500 nmol/l after ITT
29% 12-60 months
after SAH
Dimopoulou I et
al. 2004
30 Low dose ACTH
test
Total serum cortisol <
500 nmol/l after
ACTH test
10% 12-24 months
after SAH
Tanriverdi et al.
2007
22 Basal hormone
screening,
glucagon test
Total serum cortisol
<193 nmol/l, glucagon
test serum cortisol
<302 nmol/l
at 24h
22.7%, at
12
months
13.6%
24 h after
SAH and at 12
month follow-
up
ACTH=adrenocorticotrophic hormone, aSAH= aneurysmal subarachnoidal hemorrhage, ITT=insulin tolerance
test
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2.9 Etomidate in critical illness
Etomidate is a short acting anaesthetic agent used to induce anaesthesia in haemodynamically unstable patients
because it carries a low risk of hypotension (Gooding 1979; Jabre 2009; Lindeburg 1982; Reich 2005). Etomidate is
a water soluble 75% protein bound, imidazole derivative metabolized in the liver and excreted by the kidneys.
In  1983,  Ledingham  et  al.  found  that  patients  sedated  with  etomidate  for  more  than  5  days  in  the  ICU  had  a
higher mortality than patients who received a different sedation protocol (Ledingham 1983). Etomidate was
suggested to play a role in the inhibition of cortisol synthesis. After these results, several studies were performed
that showed etomidate suppressing cortisol synthesis for several hours, even after a single bolus. Etomidate has a
dose-dependent and reversible inhibitory effect on the enzyme 11--hydroxylase, which converts 11-
deoxycortisol to cortisol and causes a reduction in cortisol synthesis and elevates plasma ACTH (Allolio 1985).
Because of its haemodynamic profile,  etomidate has also been popular as an induction agent in rapid sequence
intubation of ICU patients. Because AI is common in patients with sepsis and the fact that etomidate may further
diminish cortisol production, etomidate may be relatively contraindicated in septic patients (Annane 2005).
However, if etomidate is used for patients having sepsis, steroid substitution may be recommended (Jackson
2005).
Malerba et al. (2005) studied the risk factors for AI in critically ill patients who required mechanical ventilation for
more  than  24  hours  and  showed  that  a  single  bolus  of  etomidate  suppresses  adrenal  function.  In  addition,
Mohammad et al.  (2006) showed that the incidence of relative AI determined by an ACTH stimulation test in a
retrospective  study  of  152  patients  with  septic  shock  was  higher  among  patients  who  received  etomidate  as  a
single bolus.
Because AI is common among septic patients retrospective studies have been made to find out whether septic
patients had received etomidate or not. In the study of Sprung et al. (2008) the originally effects of hydrocortisone
in septic shock were investigated. Patients who received etomidate (~20%) had a higher mortality than patients
who did not receive etomidate.
Recently a substudy of the Corticus study was published by Cuthbertson et al. (2009), who showed that a single
bolus  of  etomidate  in  patients  with  septic  shock  may cause  increased  mortality  and an  inadequate  response  to
corticotropin.
Moreover,  etomidate is a risk factor for AI when used as an induction agent in paediatric meningococcal sepsis
(den Brinker et al. 2005).
However, there are studies showing that a single bolus of etomidate does not cause excess mortality in critically
ill  patients  (Ray  2007),  and  that  it  may  be  safe  for  patients  needing  intubation  in  the  emergency  department
(Schenarts 2001). Patients with abdominal septic shock who were anaesthetized using etomidate did not have a
higher mortality than patients who were anaesthetized with other anaesthetics (Riche 2007).
Recently, Jabre et al. (2009) compared etomidate and ketamine for emergency intubation in critically ill patients
and found that ketamine is safe to use in these patients. Etomidate causes more AI than ketamine, but etomidate
does not cause excess morbidity or mortality among trauma or septic patients.
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3 Aims of the study
The objective of the present study was to evaluate the pituitary and adrenal response in critically ill patients. The
specific objectives were:
1)  To  study  the  effects  of  a  single  bolus  of  etomidate  on  serum  cortisol  concentrations.  To  compare  the
haemodynamic effects, particularly the incidence of hypotension, of propofol and etomidate when used to induce
anaesthesia in patients with severe aortic stenosis.
2) To assess the relationship and behaviour between total and calculated free cortisol concentrations in severe
sepsis and septic shock. To evaluate the predictive power of calculated free and total serum cortisol in regard to
hospital mortality in sepsis and septic shock.
3) To characterise the function of the HPA axis acutely and over time (up to 3 months) in patients with aSAH. To
assess if secondary AI is present. To investigate if disease severity and endocrinological changes correlate. To
assess the relationship, behaviour, and capability of detecting AI of calculated serum free compared to total
cortisol concentrations in aSAH.
4)  To  characterise  the  acute  behaviour  of  IGF-I  and  GH  in  acute  aSAH  (up  to  3  months)  and  to  relate  these
findings to morbidity assessed by GOS and HRQoL at 3 months.
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4 Patients and methods
4.1 Patients
A total of 237 critically ill patients were enrolled in the study. Sixty-six patients had severe aortic stenosis, 125
patients had severe sepsis or septic shock, 30 patients had acute aSAH, and 16 patients served as controls. Patient
demographics are partly presented in Table 3.
Aortic stenosis was defined as severe because of the need for surgical intervention. Severe sepsis and septic shock
were defined according to the American College of Chest Physicians/Society of Critical Care Medicine criteria
(Bone 1992). Acute aSAH was defined as evidence of cerebral vascular aneurysm and subarachnoid bleeding
within 72 hours of study entry.
Studies I, III, and IV were performed at Kuopio University hospital. Study II was a multicentre substudy of the
Finnsepsis (Karlsson 2007) study performed in the majority of Finnish intensive care units.
Table 3. Patient demographics and study inclusion criteria. Data are presented as ± SD when appropriate.
Study I Study II Study III+IV
Study design Double-blind
randomized
Prospective cohort Prospective cohort
Number of patients 66 125 46
Inclusion criteria Elective operative
treatment of aortic
stenosis
Severe sepsis or septic
shock
Acute aneurysmal SAH
Age (years) 65 ± 9 59 ± 15 52 ± 13
SAPS II score - 41 ± 15 30 ± 13
APACHE II score - 23 ± 9 15 ± 6
Hospital mortality (%) 0 21% 10%
24
4.2 Exclusion criteria
Patients under 18 years of age were excluded from all studies. In study I, the exclusion criteria were known
adrenocortical insufficiency, chronic corticoid therapy, porphyria, allergy to any of the induction agents, a BMI
exceeding 35 kg/m2, expected intubation difficulty, gastric reflux disease, a serum creatinine level above 160
mmol/l,  and  other  types  of  valvular  heart  disease.  In  study  II,  the  exclusion  criterion  was  corticoid  therapy  at
study entry. In study III, any corticoid treatment (including inhaled), use of etomidate before study entry or
during the study period, unknown exact bleeding day, previous history of aSAH, bleeding for more than 3 days
before  inclusion,  traumatic  aSAH,  known  pituitary  insufficiency,  and/or  a  moribund  state  of  the  patient  were
exclusion criteria. In the control group, the exclusion criterion was also endovascular treatment of the aneurysm.
4.3 Methods
4.3.1 Study design
All studies were approved by the local ethics committee.
Study I
Study I was a double-blind randomised study comparing the haemodynamic effects of etomidate and propofol in
patients scheduled for elective aortic valve replacement due to severe aortic stenosis. We also evaluated the
effects of these drugs on cortisol synthesis.
Sixty-six  patients  (n=33  each  group)  were  enrolled  in  this  study (Fig.  3).  All  patients  over  18  years  of  age  and
scheduled for elective aortic valve replacement due to aortic stenosis were assessed for eligibility for the study.
The patients provided informed written consent to participate in the study and the hospital ethics committee
approved the study protocol. Serum cortisol concentrations were measured in 24 patients who received etomidate
and 26 patients who received propofol.
Our hospital pharmacy randomised the patients to receive either propofol (Propofol Lipuro, BBraun, Melsungen,
Germany) or etomidate (Etomidate Lipuro, BBraun) in lipid emulsion in identical 20-ml syringes, which were
coded. Sealed opaque envelopes were used for randomisation. The clinicians were unaware of which induction
agent was being used. When the study was completed and all patients had been recruited, the drug codes were
opened. Patients were pre-medicated with 0.2 mg/kg oral diazepam 1 h before entering the operating room and
were monitored using an arterial line and a pulmonary artery catheter, both inserted before anaesthesia
induction. The bispectral index (BIS; A-1000, Aspect Medical System, Natick, MA) was used to titrate the
induction agent, achieving a BIS of 60 or less. Induction agents were given in small boluses. Alfentanil (50 mg/kg)
and pancuronium (0.1 mg/kg) were administered when BIS of 60 was achieved. Intubation was performed 3 min
after the administration of pancuronium. The mean arterial pressure (MAP) and heart rate (HR) were collected in
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a database every 10 s. The median of five consecutive values were used for statistical analysis. The median values
were collected at different time points: -1, before induction; 0, at the time of induction; 1, BIS of 60; 2, 2 min after
BIS of 60. The cardiac output and pulmonary capillary wedge pressure (PCWP) were measured when patients
were awake before the induction of anaesthesia and 2 min after induction.
The mean value of three consecutive measurements was used. An episode of hypotension was the main end-
point  of  the  study.  If  the  MAP  decreased  below  70  mmHg  for  more  than  30  s,  a  minimum  of  0.05  mg
phenylephedrine was given. We did not use a protocol for fluid therapy; this was left to the discretion of the
attending anaesthesiologist. No inotropic drugs were given during the study, which ended at the time of
intubation. Total serum cortisol concentrations were measured before the operation at 08:00 h, immediately after
the operation, and the next morning at 08:00h.
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Figure 3. Flow chart for study I.
Assessed for eligibility (n=112)
Enrollment (n=66)
Excluded (n=46)
Mitral insuffiency:5 patients
Major aortic surgery:1 patient
Using cortikoids:10 patients
No research personal available:30 patients
Randomization
Propofol
Allocated intervention (n=33)
Received allocated intervention(n=32)
Did not receive allocated intervention
(n=1)
reason:mitral insuffiency
Etomidate
Allocated intervention (n=33)
Received allocated intervention (n=32)
Did not receive allocated intervention
(n=1)
reason:medication timing mistake
Analyzed n=30
Excluded n=2
reasons:data collection failure
 Analysed n=30
Excluded n=2
Reason: data collection failure
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Study II
Study  II  was  a  prospectively  defined  substudy  of  Finnsepsis  (Karlsson  2007),  which  was  a  prospective
observational cohort study investigating the incidence, associated organ failures, and outcome of severe sepsis in
Finland. In our study, the aim was to assess the relationship between total and calculated free cortisol in severe
sepsis and septic shock. In addition, we evaluated the predictive power of calculated free and total serum cortisol
with regard to hospital  mortality in sepsis and septic shock. A flow-chart of the study is presented in Figure 4.
The ethics committee approved the study. Study entry was the time when all criteria for severe sepsis were met.
Blood samples were obtained after receiving written informed consent within 24 h of a definitive diagnosis of
sepsis or septic shock.
The cut-off values for free cortisol were based on previous studies (Annane 2006; Hamrahian 2004; Moran 1994).
A free cortisol concentration of less than 22 nmol/l and total cortisol concentration of less than 275 nmol/l was
considered to be absolute AI (Annane 2006). A free cortisol concentration between 22 and 55 nmol/l (Hamrahian
2004; Marik 2003) and total cortisol concentration between 275 and 500 nmol/l (Marik 2003), or alternatively
between 275 and 690 nmol/l (Marik 2003), were used to define relative AI.
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Figure 4. Flow chart for study II.
Finnsepsis
n=470
Blood sample taken
N=250
No blood sample
N=220
No corticoids before
blood sample n=125
Corticoids before
blood sample
N=125
Survived
N=99 (79%)
Died
N=26 (21%)
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Study III
Study III was a prospective cohort study aiming to characterise the behaviour of ACTH, total cortisol, stimulated
total  cortisol,  and free  cortisol  in  acute  aSAH.  The  control  group consisted  of  patients  over  the  age  of  18  years
who were scheduled for elective unruptured aneurysm surgery. All patients aged 18 years or older who were
treated for aSAH and admitted to the Kuopio University Hospital in Finland between 29 March and 30 November
2006 were prospectively assessed for eligibility. Only surgical patients were enrolled in the control group because
the pre-scheduled hospital stay for patients with embolised aneurysms was too short. The hospital ethics
committee approved the study protocol, and informed written consent was obtained from the patients or their
next of kin. A flow chart of the study is presented in Figure 5.
The following blood samples were collected from patients with subarachnoid haemorrhage the first to the
seventh morning after bleeding: serum (s) cortisol (reference value, 170-540 nmol/l), s-corticoid-binding globulin
(s-CBG; male reference value, 22-55 ng/l; female reference value, 40-154 ng/l), and s-albumin (reference value, 36-
45 ng/l). Samples for ACTH analysis (reference value, 0-11 pmol/l) were collected on the first and seventh days.
An ACTH-stimulating test (250 μg of tetracosactide [Synachten, Ciba-Geigy, France] administered intravenously)
was performed on the first morning in the ICU and 7 days after the bleeding. A total cortisol response of less than
248 nmol/l to exogenous 250 μg ACTH (Annane 2000) was used as a marker of relative AI.
On the second and sixth days in the ICU, 24-hour urinary cortisol excretion (reference value, 100-380 nmol) was
measured.
Equivalent blood samples were collected from control patients, with  the second ACTH sample collected on day
5. The first cortisol samples were drawn and an ACTH test performed the day before surgery and post-operative
day 5 before discharge. On day 2, 24-hour urinary cortisol excretion was measured.
At the scheduled three-month follow-up visit, the total serum cortisol concentration was measured and free
cortisol concentration calculated at 9 am, followed by an ACTH-stimulation test in both groups.
We used a random total serum cortisol concentration of less than 500 nmol/l to indicate AI (Aron 2007; Marik
2003). For free cortisol, we used a concentration of less than 55 nmol/l as the cut-off for a risk of AI (Hamrahian
2004).  We  also  tried  to  identify  patients  with  low  total  (less  than  350  nmol/l)  and/or  free  (less  than  22  nmol/l)
serum cortisol concentrations and a low serum ACTH concentration (less than 5 pmol/l) to search for those at risk
of secondary AI (Aron 2007).
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Figure 5. Flow chart of aSAH patients and controls in studies III and IV (Figure 1 in the original article for study
III). Seventeen patients with aSAH underwent endovascular treatment and 13 patients underwent open surgery.
Study IV
n=30 included in
the acute phase
analysis
n=26 patients
included in the
final analysis at
3 months
n=16 included in
the acute phase
analysis
n=16 controls
included in the
final analysis at
3 months
n=4 excluded
-3 died
-1 pregnancy
n=76
SAH patients
assessed for
eligibility
n=56  with aSAH
n=40
control patients
scheduled for
elective cerebral
aneurysm surgery
n=26 with
cerebral
aneurysm
surgery
n=20 excluded
-11 no aneurysm
-9 traumatic SAH
n=26 excluded
-9 moribund or died
-6 time of bleeding
unknown
-5 glucocorticoid
medication
-3 screening failures
-2 refused
-1 referred to other
hospital
n=14 excluded
-endovascular treatment
n=10 excluded
-glucocorticoid
medication
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Study IV was a prospective cohort study aiming to characterise the acute behaviour of IGF-I and GH in aSAH and
up to 3 months afterwards. We evaluated the relationship between IGF-I, morbidity assessed by GOS and health
related quality of life (HRQoL) 3 months after aSAH and hypothesized that low cumulative IGF-I concentrations
may negatively influence morbidty. Study IV was a substudy of study III, and the same patients were used for
data analysis.
The following blood samples were collected from aSAH patients the first to the seventh morning after bleeding:
serum (s) GH (reference value, 0-11.5 mU/l), s-IGF-I (reference values for ages 21-30 years, 15-45 nmol/l; 31-50
years, 14-36 nmol/l; 51-70 years, 10-29 nmol/l; and >70 years, 8-23 nmol/l). In control patients, the corresponding
blood samples were collected from the first to the fifth post-operative day after the patients were discharged.
Additional routine daily laboratory parameters, such as electrolytes, were recorded.
At  the  scheduled  three-month  follow-up  visit,  s-GH  and  s-IGF-I  samples  were  collected  at  9  am,  and  a  15-
dimension quality of life assessment (Sintonen 2001) was performed. We used age and sex-matched IGF-I-
concentration to determine low IGF-I and suspected GH deficiency. We also used IGF-I levels of less than 11
nmol/l as the cut-off for low IGF-I (Hartman 2002).
The health-related quality of life (HRQoL) was measured using the 15D scale (www.15d-instrument.net) (Sintonen
2001), a generic and standardised HRQoL instrument consisting of 15 dimensions: mobility, vision, hearing,
breathing, sleeping, eating, speech, elimination, usual activities, mental functioning, discomfort and symptoms,
depression, distress, vitality, and sexual activity. Each dimension has five grades of severity. For each dimension,
the respondent must choose one of the five levels (best level = 1; worst level = 5) that best describes his or her state
of  health  at  the  moment.  The  results  of  the  15D  can  be  presented  as  a  single  index  or  as  a  profile  of  all  15
dimensions. A change of 0.02–0.03 points in the health utility index or 15D score was considered clinically
important. The values on a 0–1 scale reflect the levels relative to no problems in the dimension (1) and to being
dead (0).  The mean score of the Finnish population aged 50-59 years was previously measured to be 0.92 (0.91-
0.92) (Mattila 2009). In this study, HRQoL-indexes were classified into three groups: normal (0.8 - 1.0), limited (0.6
- 0.79), and poor (<0.6).
4.3.2 Laboratory methods
All laboratory analyses were performed in Kuopio University Hospital.
We used our laboratory’s 08:00 h reference range of 170–540 nmol/l for the total serum cortisol concentration in all
studies.
In study I, enzyme immunoassay (DPC Immulite 2000; Cortisol DPC, Los Angeles, CA) was used to measure total
cortisol in the serum. All cortisol samples were analysed immediately following collection.
In studies II and III, blood samples were stored for late analysis at -80°C and -70°C, respectively. In both studies,
the same personnel performed all analyses in one laboratory at the Kuopio University Hospital. We used
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electrochemiluminescence immunoassay (Elecsys Cortisol, Roche Diagnostics, Mannheim, Germany) as the
diagnostic method.
The Coolens equation was used to calculate the concentration of free cortisol in serum (Coolens 1987): U2K (1 + N)
+ U [1 + N + K (G- T)] - T = 0, where K= 3 × 10-7 M-1(affinity of CBG to cortisol at 37°C), G = CBG, U = unbound
cortisol, T = cortisol, and N = ratio of albumin bound to free cortisol (1.74). U was calculated as follows:
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Serum CBG concentrations were analysed by radioimmunoassay (BioSource Europe S.A., Nivelles, Belgium).
After dichloromethane extraction, free urinary cortisol concentrations were analysed using the same method
employed for measuring total serum cortisol. Plasma ACTH concentrations were analysed using an
immunoluminometric assay (IMMULITE; Diagnostic Products Corporation, Los Angeles, CA).
In study II, an ACTH stimulation test was performed. Tetracosactide (0.25 mg; Synachten, Ciba-Geigy, France)
was administered intravenously and serum cortisol concentrations analysed 30 and 60 minutes later.
Serum  GH  concentrations  were  analysed  using  specific  time-resolved  fluoroimmunoassay  (TR-FIA)  by
AutoDelfia (PerkinElmer Life and Analytical Sciences Wallac Oy, Turku, Finland). Serum IGF-I concentrations
were analysed using a quantitative sandwich enzyme immunoassay (ELISA) technique (Quantikine Human IGF-
1 Immunoassay; R&D Systems, Minneapolis, MN, USA).
4.3.3 Statistical methods
Studies I and III were based on sample size calculations. In both studies, a power of 80% and a two-sided -level
of 0.05 were used. In study I, propofol was assumed to decrease blood pressure in 50% of patients, and etomidate
was assumed to do so in 10% of patients. A decrease in blood pressure was arbitrarily defined as MAP<70 mmHg
for more than 30 s.  In study III,  we assumed that 25% of patients with aSAH and none of the elective surgical
patients would develop AI.
Generally, data are presented as mean ± standard deviation (SD), as absolute values and percentages, or as
medians and interquartile ranges. Parameter distribution was assessed using the Kolmogorov-Smirnov test. For
normally distributed parameters, the student's t-test  was  used  to  compare  the  means  of  different  groups.  The
Mann-Whitney  U  test  was  used  for  nonparametric  testing  between  groups.  In  study  I,  analysis  of  variance
(ANOVA) was used for repeated measurements between groups.
In  studies  III  and  IV,  a  mixed  models  method  was  used  for  testing  between  the  groups,  allowing  for
heterogeneity between the groups. The Bonferroni correction was used to adjust for multiple testing. In all
studies, Spearman and/or Pearson correlations were used depending of the distribution of the data.
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In study II, predictive power regarding hospital mortality was assessed by areas under the receiver operating
curves (AUC). Outcomes were presented according to the Kaplan–Meier method, and groups were compared
using the log-rank method.
All statistical analyses were performed using SPSS software (SPSS, Chicago, Ill, USA).
To  identify  the  factors  associated  with  poor  HRQoL  or  death,  we  constructed  a  Bayesian  prediction  model  in
aSAH patients using P-course. P-course is a web-based Bayesian classifier that is able to use multidimensional
priors; for example, separate priors for the outcome variable in general and for the outcome variable according to
each predicting variable. The methods have equalled or outperformed novel logistic regression, especially in
small data sets in terms of prediction accuracy (Lau 2002; Ng 2002), variable selection, and multiple performance
measures.  The  methods  perform  well  with  incomplete  or  complex  data  typical  to  small  data  sets.  This  data
modelling was achieved without informative a priori information.
The outcome variable was poor HRQoL measured by 15D and dichotomized into normal (0.80 - 1.00) or poor (0 -
0.79), where the value 0 indicates death. In the first phase, there was a set of 355 potential predicting variables. By
using  the  P-course  classifier,  this  number  was  reduced  to  22  variables  from  30  aSAH  patients.  To  avoid  over-
fitting the model, we formed four sets of 25 randomly selected patients, and a prediction model was made for
each set. We obtained four slightly different sets of prediction variables.
34
5 Results
5.1 Effect of etomidate on the cortisol response in patients with aortic stenosis
Table 4. Anaesthetic and haemodynamic data of the patients from study I.
NS = not significant
The effect of a single bolus of etomidate on cortisol concentrations and haemodynamic parameters was studied in
study I. Anaesthetic data are presented in Table 4. Etomidate caused a transient depression of the serum cortisol
concentration in patients with severe aortic stenosis (Fig.  6), and it blocked the acute cortisol response to acute
stress  caused by  open heart  surgery.  Etomidate  caused less  hypotension  than  propofol  in  patients  with  severe
aortic stenosis (Fig. 7).
Pre-operative serum cortisol concentrations were comparable in both groups (Fig. 6). Cortisol concentrations
immediately after the operation were lower in the patients who received etomidate, but no difference was
observed the next morning. The difference in cortisol concentrations between the two measurement points was
404±27 nmol/l in the propofol group and -34±162  nmol/l in the etomidate group (p<0.001).
Etomidate group Propofol group p-value
Anaesthetic dose in mg
(range)
13 (4-20) 77 (40-400) -
Aortic stenosis
gradient (mmHg)
75 ± 14 75 ± 18 NS
Phenylephedrine dose
(mg)
0.14 ± 0.08 0.14 ± 0.08 NS
Patients needing
phenylephedrine
before intubation
8 20 0.002
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Figure 6. Serum cortisol concentrations before, immediately after, and the morning after surgery. Baseline cortisol
concentrations were not different between groups. Immediately after the operation, the cortisol concentration was
lower in the patients who received etomidate (p<0.001). Serum cortisol levels are presented as mean ± SD.
Aortic occlusion times were similar in both groups (propofol 116±35 min vs. etomidate 112±38 min, p=0.68). There
was  no  difference  in  the  perfusion  time  between  the  groups  (propofol  140±39  min  vs.  etomidate  137±45  min,
p=0.78). There were no differences between the patients who received propofol or etomidate in regards to length
of ICU stay, number of re-operations,  incidence of infection after operation, re-admission rate to ICU, length of
hospital stay, hospital mortality, or postoperative serum creatinine MBm-fraction concentration.
MAP
0
20
40
60
80
100
120
-1 0 1 2
MAP
(mmHg)
Etomidate
Propofol
p=0.006
Figure 7. Time course of MAP. The MAP decreased in both groups (p=0.001). Propofol decreased the MAP more
than etomidate (p=0.006). Data are presented as mean ± SD. Time points refer to the following time course:-1,
before induction; 0, the time of induction; 1, BIS  60; 2, minutes after BIS60.
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The correlation between the administered etomidate dose and serum cortisol concentration is presented in Figure
8.
y = -6,8857x + 361,25
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300
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Concentration
(nmol/l)
Figure 8. An inverse correlation between the administered etomidate dose and immediate postoperative serum
cortisol concentration. Correlation coefficient = -0.453, p<0.026. Two cortisol concentrations at 4 mg etomidate (264
nmol/l and 265 nmol/l) and 8 mg etomidate (242 nmol/l and 244 nmol/l) overlap.
5.2  Free and total cortisol in severe sepsis and septic shock
The  relationship  and  association  between  outcome  and  free  and  total  serum  cortisol  concentrations  in  severe
sepsis and septic shock was evaluated in study II. The causes of sepsis were pneumonia (n=53), intra-abdominal
infection (n=35), cellulitis (n=14), urinary tract infection (n=7), central nervous system infection (n=5), endocarditis
(n=5), head/neck infection (n=2), and unknown (n=8). The hospital mortality was 21%. Detailed mortality data are
presented in Table 5.
No difference in mortality was detected between patients who received corticoids (n=35) and those who did not
receive corticoids (n=90; p=0.18) after blood samples were drawn. There was also no difference in mortality
between patients who received corticoids for sepsis and those who did not.
Patients who received hydrocortisone had higher baseline total serum cortisol concentrations than patients who
did not receive hydrocortisone (1030±460 nmol/l vs. 707±385 nmol/l, p=0.002), higher calculated free cortisol
concentrations (234 ±145 nmol/l vs. 118±112 nmol/l, p=0.001), and higher free/total serum concentrations (21±7%
vs.14±7%, p<0.001).
Absolute  AI,  in  terms  of  calculated  free  serum cortisol  <22  nmol/l,  was  detected  in  12  patients,  and all  of  them
survived. Altogether, 25 patients (20%) had relative AI, in terms of calculated free serum cortisol <55 nmol/l, and
three  of  the  patients  died  in  the  hospital.  Four  patients  with  relative  AI,  in  terms  of  calculated  free  cortisol
concentrations <55 nmol/l, received corticoids, three of whom died. The remaining 88 patients had free cortisol
concentrations > 55 nmol/l; their hospital mortality was 26%.
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Absolute AI, in terms of total serum cortisol <275 nmol/l, was detected in 10 patients, and all survived. Relative
AI,  in terms of total serum cortisol concentration <500 nmol/l,  was detected in 27 patients,  three of whom died.
Relative AI, in terms of total serum cortisol concentration <690 nmol/l, was detected in 58 patients, nine of whom
died (13%; p=0.023)
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Nonsurvivors had higher free, total, and free/total serum cortisol concentrations than survivors. The cortisol
concentrations in survivors and non-survivors are presented in Table 6, and the concentration in patients who
received or did not receive hydrocortisone treatment in Table 7.
Table 6. Cortisol concentrations in survivors and nonsurvivors.
Survivors (n=99) Nonsurvivors (n=26) p-value
APACHE II score 21±9 28±8 0.001
SAPS II score 39±14 52±16 <0.001
SOFA on day 1 7±3 9±3 0.009
Serum total cortisol
(nmol/l)
704±383 980±458 0.002
Free cortisol
(nmol/l)
119±111 209±151 0.002
Free/total 14±7 19±7 0.003
CBG (μg/ml) 31±12 27±11 0.1
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Table 7. Demographic data for patients who received glucocorticoid treatment after blood samples were taken
and patients who did not receive glucocorticoid treatment.
No glucocorticoid
treatment
(N=90)
Glucocorticoid treatment
(N=35)
p-value
Age (years) 59±16 59±14 0.99
No. of males 65 (72%) 25 (71%) 0.93
APACHE II score 21±10 25±8 0.07
SAPS II score 40±15 45±16 0.10
SOFA on day 1 7±3 8±3 0.11
ICU mortality, N (%) 8 (9%) 6 (7%) 0.19
Hospital mortality, N (%) 16 (18%) 10 (28%) 0.18
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The  AUCs  for  calculated  free  and  total  serum  cortisol  concentrations  are  presented  in  Figure  9.  We  found  no
superiority of free or total serum cortisol concentration or the free-total cortisol ratio in assessing mortality.
Figure 9. Receiver operating characteristic curves regarding hospital mortality for total (A) and free (B) serum
cortisol. The area under the curve (AUC) for total serum cortisol was 0.68 (CI 0.57-0.80), and for free cortisol was
0.70 (95% CI 0.60-0.81).
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In general, there was a good correlation between calculated free and total cortisol (Spearman correlation
coefficient 0.90, p<0.001; Fig. 10).
Figure 10. Baseline total and free serum cortisol concentrations. Spearman correlation coefficient 0.90, p<0.001.
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No difference in mortality was detected when comparing free and total serum cortisol concentrations using cut-
off values of 500 nmol/l for total serum cortisol or 55 nmol/l for free serum cortisol (Fig. 11).
Figure 11. Kaplan-Meier curves for (A) total serum cortisol greater than or less than 500 nmol/l (p=0.054) and (B)
free serum cortisol greater than or less than 55 nmol/l (p>0.1).
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5.3 Pituitary-adrenal function in acute aneurysmal subarachnoid haemorrhage
Study  III  investigated  the  ACTH-cortisol  response  in  acute  aSAH.  Thirty  patients  with  aSAH  and  16  control
patients assessed for elective cerebral aneurysm surgery were enrolled in the study (Table 8).
Table 8. Demographic  data  of  the  patients  in  study  III.  Data  are  presented  as  numbers  or  mean  ±  SD  unless
otherwise indicated. ICA=internal carotid artery, MCA=median cerebral artery, AcoA=anterior communicating
artery, ACA=anterior cerebral artery, VBA=vertebrobasilar artery, ICU=intensive care unit, HDU=high
dependency unit, LOS=length of stay, SAPS=Simplified Acute Physiology Score, Apache=Acute Physiology and
Chronic Health Evaluation
aSAH
Clipped
(n=13)
aSAH
Coiled
(n=17)
p-value for
clipped vs.
coiled
Control (n=16) p-value for
aSAH vs.
controls
Age, years (range) 50 (25-73) 54 (21-78) 0.53 50 (37–64) 0.53
Gender M/F 5/8 9/8 0.41 4/12 0.15
Aneurysm location
 ICA
 MCA
 ACoA
 ACA distal
 VBA
2
8
1
1
1
4
0
10
1
2
6
10
0
0
0
Hydrocephalus on
admission
2 4 0
Fisher grade
 I–II
 III–IV
2
11
2
15
Hunt & Hess initial
 I–II 5 10
 III 3 3
 IV–V 5 4
SAPS II 27 ± 12 33 ± 14 0.27
APACHE II 14 ± 5 16 ± 6 0.53
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Daily free and total serum cortisol concentrations were measured up to day 5 for control patients and day 7 for
aSAH patients. The aSAH patients had higher cortisol concentrations than control patients only at day 1 (Fig. 12).
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Figure 12. Free and total serum cortisol concentrations. Patients with aSAH had higher initial (A) total serum
cortisol (p = 0.001) and (B) free serum cortisol concentrations (p < 0.001) than control patients. At later time points,
there were no differences between the groups. Data are presented as median, interquartile ranges, and outliers.
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Free and total serum cortisol concentrations correlated well (Fig. 13).
Figure 13. Pooled data and quadratic regression analysis was used to produce this figure. The equation from
quadratic regression analysis for free serum cortisol concentration was 0.024 × total serum cortisol concentration +
0.0000772 × total cortisol concentration². The Pearson correlation coefficient was 0.88, p<0.001. The dependence of
free cortisol on total cortisol shows the expected hyperbolic increase of free cortisol with total cortisol until CBG is
saturated, when the relation becomes linear.
The GCS status, Hunt & Hess grade, Fisher grade, norepinephrine treatment, hydrocephalus, hypoalbuminemia,
and hyponatremia did not affect the free or total serum cortisol concentration. The ACTH concentrations were
similar in patients with aSAH and in the control group. In this study, two patients were susceptible to secondary
AI due to low ACTH and free and/or total serum cortisol on the first and seventh day. Additionally, two patients
had isolated low free serum cortisol and normal total cortisol but low ACTH.
Location (anterior communicating artery vs. other artery) did not affect serum ACTH or free or total serum
cortisol concentrations.  Patients with a Hunt & Hess grade of IV–V had higher ACTH concentrations at days 1
(10.7 ± 7.1 pmol/l)  and 5 (8.2 ± 7.7 pmol/l)  compared to patients with Hunt & Hess grade I–III  (day 1,  3.8 ± 2.0
pmol/l, p = 0.002; day 5, 4.7 ± 1.8 pmol/l, p = 0.04). The GCS (<8 or >8), Fisher grade (I–II vs. III–IV), and presence
of hydrocephalus did not affect ACTH concentrations.
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The 24-hour free urinary cortisol concentration was 4896 ± 5342 nmol/l in patients with aSAH and 1641 ± 1601
nmol/l in the control group on day 2 (p = 0.001). On day 6, the 24-hour free urinary cortisol concentration was
3276 ± 3710 nmol/l in patients with aSAH.
The response to exogenous ACTH is shown in Figure 14.
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Figure 14.  Response  to  exogenous  ACTH in  aSAH and control  patients.  No significant  differences  were  found
between the groups. The percentage of patients with a serum cortisol response of less than 248 nmol/l  was also
not  different  between  the  groups.  On  day  1,  8  (33%)  patients  with  aSAH  and  8  (50%)  control  patients  had  a
cortisol response of less than 248 nmol/l (p =0.11). At day 5 and 3 months, one patient with aSAH and no control
patients had a cortisol response of less than 248 nmol/l (not significant). The patient with a failed Synachten test at
3  months  also  failed  the  first  and  second  test.  Test  1=day  1;  test  2=day  5  (control)  or  day  7  (aSAH);  test  3  =  3
months. Data are presented as median, interquartile ranges, and outliers.
On day 1, a higher proportion of patients with aSAH had free and total serum cortisol concentrations of less than
55 nmol/l or 500 nmol/l, respectively (Fig. 15).
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Figure 15. Percentage of patients with a baseline free serum cortisol concentration < 55 nmol/l or total serum
cortisol concentration <500 nmol/l. *p=0.046 for difference between the groups on day 1. **p<0.001 for difference
between the groups on day 1.
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5.4 Effect of aneurysmal subarachnoid haemorrhage on the GH-IGF-I response
The patient population from study III was used in study IV. Serum GH and IGF-I concentrations are presented in
Table 9 and in Figure 16. IGF-I levels were significantly lower in patients with aSAH compared to control patients
on days 1-5 (p=0.01), but no difference was found at 3 months. Serum GH concentrations were similar in aSAH
and control patients.
Table 9. Serum GH and IGF-I concentrations. Data are presented as mean ± SD.
GH IGF-I
aSAH Control p aSAH Control p
Day 1 3.4 ± 5.5 1.6± 2.7 0.18 8.2 ± 3.1 10.5 ± 2.7 0.04
Day 2 3.5 ± 5.5 4.5 ± 5.3 0.48 8.4 ± 3.6 11.9 ± 3.1 <0.01
Day 3 3.0 ± 5.3 1.8 ± 1.6 0.37 8.1 ± 4.2 11.4 ± 4.2 <0.01
Day 4 2.4 ± 4 3.5 ± 4.5 0.54 7.8 ± 3.9 10.9 ± 3.8 0.01
Day 5 2.0 ± 2.1 2.4 ± 3.7 0.72 8.0 ± 4.4 11.1 ±  4.1 <0.01
Day 6 2.1 ± 2.4 7.8 ± 4.0
Day 7 1.6 ± 2.4 7.7 ± 4.0
3 months 2.0 ± 5.1 3.7 ± 5.0 0.23            9.7 ±3.1 10.4 ±  2.4 0.9
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Figure 16. Serum IGF-I concentrations in aSAH and control patient. p=0.01 for the difference between groups on
days 1-5 and p=0.9 for the difference at 3 months.
The  mean  IGF-I  concentration  in  aSAH  patients  for  days  1-5  was  8.1  ±  3.5  nmol/l  and  11.2  ±  3.1  nmol/l  in  the
control group. Ten patients in the aSAH group had a GOS of 4 or less,  and the others had a GOS of 5.  Patients
with a GOS 4 had a lower quality of life than patients with a GOS=5 (0.7 vs.0.88, p=0.003).
Figure 17 represents the distribution of IGF-I in respect to different cut-off levels. No statistically significant
differences were found in the proportion of having lower than age related IGF-I reference values between
patients with aSAH or controls.
Hunt and Hess grade, Fisher grade, and the presence of hydrocephalus or vasospasm were not associated with
the level of IGF-I concentration, either < 11 nmol/l or > 11 nmol/l.
In patients with aSAH, there were no differences in IGF-I or GH concentrations between the patients in respect to
aneurysm location (anterior communicating artery versus others), treatment modality (clip vs. coil), Hunt-Hess
grades (I-III versus IV-V), Fisher grade (I-II versus III-IV), GCS (< 8 or >), symptomatic vasospasm and/or need for
Day 1 Day 2 Day 3 Day 4 Day 5 3 months
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norepinephrine (n=9), or hydrocephalus on admission.  Gender or BMI did not affect IGF-I or GH concentrations.
Age was negatively correlated with IGF-I (r=-0.31, p=<0.001).
The  mean 15D HRQoL sum in  patients  with  aSAH was  0.81  ±  0.16  and in  control  patients  0.86  ±  0.09  (p=0.24).
Quality of life was moderately low (<0.8) in 6 patients with aSAH and in 5 control patients (p=0.75).  In addition, 3
patients with aSAH and none of the control patients had poor quality of life (<0.6).   The HRQoL dimensions of
speech (p=0.04) and eating (p=0.03) were lower in patients with aSAH than in the control group; otherwise,  no
statistically significant differences were observed in the scores between the groups.  Ten patients in the aSAH
group had 4 or less on the Glasgow outcome scale (GOS), and the others had GOS 5.  Patients with GOS  4 had
lower quality of life than patients with GOS 5 (0.7 vs.0.88, p=0.003). Additionally, patients with GOS  4 had lower
mean IGF-I concentrations than patients with GOS 5 (8.3 ± 2.6 nmol/l vs. 12.7 ± 5.1 nmol/l, p=0.02). Patients with
Hunt & Hess grades IV-V had similar HRQoL than patients with Hunt & Hess grades I-III (0.73 ± 0.2 vs. 0.84 ±
0.13, p=0.12). aSAH patients with low HRQoL (<0.8) had lower mean IGF-I concentrations than patients with
good HRQoL ( 5.7 ± 2.1 nmol/l vs. 8.7 ± 3.4 nmol/l). Mean IGF-I for days 1-7 was mildly associated with HRQoL
by a Pearson’s correlation coefficient 0.36, p=0.08).
In  the  Bayesian  model,  use  of  statins  prior  to  aSAH,  hyponatremia,  SOFAmax,  and the  sum of  IGF results  for
days 1-7 after the aSAH were associated with poor HRQoL.  This model was accurate in 78.6% of cases in leave-
one-out cross validation (corresponding log-score 0.57, compared to 53.6% accuracy for the biggest class (i.e.,
default  or  educated  guess),  log-score  0.69,).   When the  model  was  tested  by  putting  the  total  material  into  the
model, an accuracy of 89% was reached.  The sensitivity was 0.86 and specificity 0.93.  The results indicate that a
low IGF level in the days following aSAH may be associated with poor HRQoL or death.
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Figure 17. IGF-I concentrations in aSAH and control patients. The line represents the cut-off level of 11 nmol/l.
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6 Discussion
We found that a single dose of etomidate suppresses cortisol synthesis for less than 24 hours in patients admitted
for elective cardiac surgery due to severe aortic stenosis. Etomidate was haemodynamically more stable than
propofol. In addition, measuring free serum cortisol in patients with severe sepsis, septic shock, or aSAH did not
show any advantages over total serum cortisol. We also showed that aSAH may cause secondary AI, and IGF-I
concentrations are low in patients with acute aSAH, which may have impact on outcome.
6.1 Critical illness-related corticosteroid insufficiency
Generally,  one of the major stress responses is the activation of the HPA axis by increasing cortisol production
(Aron 2007). Corticoids regulate inflammation, impair the vasomotor tone of the vasculature, affect the
distribution of body fluids, and sensitize the catecholamine receptors (Rhen 2005). Early studies in critically ill
patients showed that high dose corticoid treatment increases morbidity and mortality. In studies published before
1989, mortality seemed to increase, whereas mortality seemed to decrease in studies published after 1997
(Minneci 2009). The main difference among these studies was the steroid dose used and tapering the steroid
treatment. Since the study by Annane in 2000 (Annane 2000) that showed increased morbidity and mortality in
patients with AI, several studies attempted to determine the relevancy of possible AI in septic patients. Septic
patients are generally thought to need corticoid replacement therapy, but much is to be discussed regarding why,
for whom, and on what basis this supplementary anti-inflammatory drug should be administered. Because most
of  the  critically  ill  patients  are  faced  with  enormous  stress,  other  patient  categories  have  been  evaluated  for  an
inadequate cortisol response, including patients with aSAH, TBI, coronary artery disease (Henzen, 2003), liver
failure (Marik 2005), and acute pancreatitis (Peng 2009).
CIRCI is defined as an inadequate response to corticosteroids in regards to meeting the needs of a patient.
Following this definition, the earlier concept of AI should be avoided. However, most of the studies done on this
subject have been done in patients with sepsis; thus, the CIRCI definition may not be adequate for patients with,
for  example,  aSAH.  As  shown  in  our  study,  secondary  AI  may  predominate  in  aSAH.  The  adequacy  of  the
cortisol response in relation to disease severity remains unclear and needs to be studied further.
There are three main methods of defining adequate serum cortisol concentrations in critically ill patients: random
serum cortisol concentration, a response to ACTH stimulation, and clinical judgement and vital parameters, such
as hypotension. Obviously, the incidence of possible AI due to cortisol deficiency varies greatly depending on
which criteria are used to define the problem (Bernard 2006). Several random serum cortisol definitions are used
to determine AI in critical illness (Bernard 2006; Cooper 2003; Lipiner 2007; Marik 2003), and we showed that one
individual patient can be categorized as having AI and not having AI depending on whether free or total serum
cortisol concentrations are used.
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Although timing of cortisol measurements is essential in critical illness, the circadian rhythm of serum cortisol
concentration variation may be disturbed (Voerman 1992). Moreover, morning cortisol samples are not
standardised. Typically, major nursing procedures with potentially high stress stimuli, may precede cortisol
sampling. From this perspective, an ACTH stimulation test could have some advantages over random serum
cortisol sampling.
Our  study did  not  show any difference  in  the  absolute  values  of  free  or  total  serum cortisol  concentrations  in
severe sepsis or septic shock. However, the ratio of free/total cortisol was elevated as a result of low CBG. Free
serum cortisol was not helpful in diagnosing the adequacy of serum cortisol production in patients with severe
sepsis, septic shock, or aSAH. This finding was also reported by Annane et al.(2006), but Hamrahian et al. (2004)
suggested  that  measuring  free  serum  cortisol  may  be  superior  to  measuring  total  serum  cortisol,  especially  if
patients have hypoproteinemia. Low serum albumin did not affect our serum cortisol measurements in patients
with aSAH. Free and total cortisol concentrations correlated well in patients with sepsis or aSAH. In sepsis, both
the free and total serum cortisol concentration was lower in survivors than nonsurvivors. The free serum cortisol
concentration was not helpful for distinguishing between survivors and nonsurvivors. To achieve a morbidity or
mortality difference, patients with higher initial serum cortisol levels should be given low dose hydrocortisone.
The possible effect of additional glucocorticoids in these patients may be explained by down-regulation of
glucocorticoid receptors (Molijn 1995). Thus, new recommendations for hydrocortisone treatment in sepsis are
based on clinical parameters. Although our study showed increased cortisol levels after aortic valve surgery, we
do not know if this was adequate. Corticoids may have some other additional benefits, such as reducing the risk
of atrial fibrillation after CABG surgery (Halonen 2007).
More severe sepsis resulted in higher total and free serum cortisol concentrations, which is in agreement with
other studies (Annane 2000; Lipiner, 2007; Marik 2003). Interestingly, aSAH severity did not affect free or total
serum cortisol  concentrations.  Our  study is  the  first  to  report  this  observation  in  the  acute  phase  of  aSAH,  but
other studies have demonstrated this in the chronic phase of aSAH (Aimaretti 2005; Dimopoulou 2004a;
Kreitschmann-Andermahr 2004). We found some individuals with low ACTH and total and free serum cortisol
concentrations, reflecting secondary AI, which could theoretically explain this finding. Definitive reference values
would be needed for an adequate cortisol response in aSAH compared to other diseases.
In  the  clinical  point  of  view,  corticoids  exert  many  fast  beneficial  effects,  such  as  a  diminished  need  for
norepinephrine infusions, by sensitizing catecholamine receptors (Rhen 2005). In patients with aSAH, corticoids
may  be  used  to  treat  vasospasm  for  the  same  reason,  but  it  also  may  be  used  in  some  situations  to  treat
hyponatremia (Katayama 2007). These regimens are not definitively proven in the case of aSAH. In practice, we
face  a  situation  in  which  only  recommendations  for  the  diagnosis  of  CIRCI  in  septic  patients  exist.  Taken
literately, the diagnostic criteria for CIRCI and AI should be used for critically ill patients in general. No scientific
evidence is provided for this aspect because many disease entities are not well studied.
Our  study  in  patients  with  aSAH  is  the  first  to  describe  the  behaviour  of  free  and  total  serum  cortisol
concentrations  in  the  acute  phase  of  the  disease.  Describing  the  typical  pattern  of  cortisol  response  in  aSAH is
important before judging patients as having an inadequate response. As discussed above, the critical care
55
environment and nursing procedures, sedative agents, antibiotics, body composition (Klose 2007), contraceptive
agents (Klose 2007), and cortisol assessment methods (Arafah 2006) have not been standardised in studies
investigating CIRCI or AI in critically ill patients. We may be in a situation that is described as follows: “CIRCI is
defined as inadequate cellular corticosteroid activity for the severity of the patient’s illness”; and further studies
are needed to carefully define adequacy of human stress response in different diagnosis categories.
6.2 Effects of common sedative agents used in critical illness on serum cortisol concentrations
Critically ill patients require sedatives for various indications, and continuous infusions are most commonly
applied to keep the patient adapted to ventilatory support therapy. In neurological critical care, sedatives enable
adaptation to mechanical ventilation and play an essential role in treating patients with high intracranial pressure
and/or decreased consciousness. In addition to long-lasting sedation in the ICU environment, short procedural
sedation is needed for, for example, wound care and cannulation.
Critically ill patients typically receive multiple drugs with sedative properties. Other drugs, such as antifungals,
that  affect  the  endocrinological  axis  may  also  occasionally  be  used.  This  context  makes  the  interpretation  of
endocrinological test results a challenge.
Etomidate is an old drug that raised concerns among intensivists in 1983 (Ledingham 1983) in regards to
increased mortality due to an inhibition of cortisol production in patients with multiple trauma. However, in that
particular study, etomidate was used as an infusion; since then, etomidate infusions have not been used.
Etomidate is haemodynamically stable (Gooding 1979; Reich 2005), making it an attractive drug for facilitating
intubation in critically ill patients. The haemodynamic profile has also made etomidate a drug of choice in
emergency care medicine if sedation is needed for intubation (Jabre 2009; Zed 2006). These patients are typically
suffering from various deceases that lead to ICU treatment.
The effects of a single dose of etomidate have been studied in different patient scenarios. A recent study of 479
acutely ill patients, ketamine was demonstrated to be an alternative to etomidate in these patients (Jabre 2009).
This  study is,  thus  far,  the  largest  study comparing  etomidate  to  another  drug.  This  study had two important
findings. First, etomidate can be replaced by another haemodynamically stable induction agent, ketamine.
Second, etomidate use was not associated with increased morbidity or mortality. However, only 76 septic patients
were recruited and the findings may be due to the small sample size in this subgroup. Jabres et al. (2009) study
was not powered to detect possible effects of etomidate in patient subgroups. Jabre et al.  (2009) also studied the
adrenal axis and found that etomidate suppresses the effect of the ACTH stimulation test and the baseline total
cortisol concentrations.
We must emphasize that patients with severe sepsis or septic shock may benefit from a normal functioning HPA
axis and may need cortisol substitution (Annane 2000; Sprung 2008). Cuthbertson et al. (2009) showed that a
septic patient who receives a single bolus of etomidate has a blunted response to the ACTH stimulation test, and
they may have increased mortality. Other studies of septic patients have come to the conclusion that small single
doses of etomidate may have detrimental effects (Mohammad 2006; Warner 2009), and it has been shown to be a
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risk factor for developing AI (Malerba 2005). In patients with infections and sepsis, a very reluctant attitude
towards etomidate should be expressed if it is considered as an anaesthetic agent (Annane 2005). Some authors
have suggested cortisol replacement therapy for patients who have received etomidate (Fengler 2008; Vinclair
2008).
Interestingly, animal studies for a new anaesthesia agent, methoxycarbonyl-etomidate, have been published
(Cotten 2009). Although based on very preliminary data, this etomidate analogue is very quickly metabolized,
haemodynamically stable, and does not cause adrenal gland suppression.
The results mentioned above are similar to our study; etomidate suppresses cortisol production and has a stable
haemodynamic profile. The causality of the negative effects on cortisol production and outcome in
neuroanaethesia or neurocritical care has not yet been demonstrated. No studies of HPA function and etomidate
in the context of aSAH or TBI have been published. Etomidate is used because of its minimal effects on ICP, but
the question of HPA function, cortisol, morbidity, and mortality should be raised.
However, etomidate is still commonly used worldwide, though its use is not popular in Finland. Etomidate’s
haemodynamic profile is constantly used as an argument for its use, and ketamine has been neglected,
particularly because of its tendency to increase ICP in patients with acute brain catastrophes (Himmelseher 2005).
However, this aspect was not supported in a systematic review, and it was pointed out that the haemodynamic
profile of ketamine may be beneficial in patients needing sedation for intubation because of brain trauma
(Himmelseher 2005). Ketamine does not cause decreases in serum cortisol concentrations. We showed that,
although etomidate  is  more  haemodynamically  stable,  blood pressure  is  easily  corrected  with  small  boluses  of
phenylephedrine if propofol is used as an iduction agent. Etomidate does not have enough advantages over
commonly used small doses, carefully titrated propofol, and opioid induction, at least in a controlled
environment and carefully monitored patients. The stress induced by major surgery may overcome the inhibitory
effects of a single dose of etomidate on cortisol synthesis (Crozier 1994). However, propofol causes hypotension,
which has been shown to be an independent risk factor for peri-operative complications (Arbous 2001).
Although  etomidate  has  probably  the  most  potent  suppressive  effect  on  cortisol  synthesis  among  common
sedative agents, almost all sedative agents used in ICUs have endocrinological effects. Propofol decreases
catecholamine and cortisol concentrations after CABG (Plunkett 1997), but it does not have significant effects on
steroidogenesis (Aitkenhead 1989), which is also supported by our study. Opioids have a depressant effect on
serum cortisol concentrations (Oltmanns 2005), and benzodiazepines may also cause some cortisol synthesis
depression (Crozier 1994), but it seems that midazolam does not inhibit adrenal gland function (Aitkenhead 1989;
Plunkett 1997; Shapiro 1986).
Dexmedetomidine is a new 2-agonist used for sedation in ICU patients. Similar to etomidate, dexmedetomidine
is an imidazole derivate,  thus having the potential  to inhibit  cortisol synthesis.  However,  in short-term use,  no
suppression of cortisol synthesis was detected (Venn 2001).
The complex interactions of sedative agents and other drugs make it impossible to completely control for agents
that may affect serum cortisol concentrations. With this perspective, large studies in different disease categories
with morbidity and mortality endpoints must be carried out to really detect the clinical significance of sedative
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agents on cortisol and/or other endocrinological abnormalities. Most importantly, reference values for serum
cortisol concentrations should be published for the most common critical illness subgroups.
6.3 GH-IGF-I response in neurological critical illness
GH  mediates  its  actions  via  IGF-I.  Recent  studies  have  shown  that  IGF-I  plays  an  important  role  in  neuronal
growth, apoptotic cell death, and protection against brain ischemia (Kooijman 2009). IGF-I has an essential
neuromodulatory role throughout the lifespan (Aleman 2009).  In animal models of ischemic stroke, treatment
with IGF-I was shown to possibly reduce areas of brain ischemia (Liu 2004). No studies have evaluated the role of
IGF-I  and  the  outcome  in  patients  with  aSAH.  In  prolonged  critical  illness  GH-treatment  increased  mortality
(Takala 1999)
GH insufficiency is the most vulnerable axis of brain trauma-induced pituitary insufficiency with a hypothetical
explanation of the vulnerable location of the somatotrophs (Popovic 2005). The possible GH-IGF-I insufficiency in
neurocritical illness can be approached in two ways: GH-IGF-I as an indicator of pituitary dysfunction or relative
IGF-I insufficiency mirroring its role as a neuroprotective agent.
We showed that  the  blood IGF-I  concentration  is  lower  in  patients  with  aSAH than control.  Cumulative  IGF-I
concentration was associated with morbidity assessed by HRQoL and GOS. The IGF-I concentrations were under
the cut-off levels given in other studies, more often in aSAH patients (Hartman 2002). No association between GH
and IGF-I concentrations was detected. Single GH measurements are generally agreed to be of little value if  no
GH stimulation test is performed (Gasco 2008). However, the IGF-I concentrations were not low at 3 months in
either aSAH or control patients.  This finding is not in accordance with other studies in which low values were
detected in the chronic phase of aSAH (Dimopoulou 2004; Tanriverdi 2007).
There  are  several  cut-off  limits  for  detecting  somatotroph  insufficiency  that  can  be  used  if  classical
hypopituitarism  is  the  target  to  be  detected.  On  the  other  hand,  focusing  on  the  question  of  IGF-I  and
neuroprotection is interesting. In this context,  no real cut-off limits exist  in any neurological disease.  An excess
amount of IGF-I may be needed, and IGF-I could be used as a drug for acute neurological repair (Kooijman 2009).
Bondanelli et al. (2006) reported that all patients with ischemic stroke in their study had normal age-related IGF-I
values. However, patients with lower IGF-I values have worse outcomes than patients with higher IGF-I values.
Also,  in  children  with  meningococcal  sepsis,  nonsurviving  patients  have  low IGF-I  values  (de  Groof  2002).  We
showed that patients with aSAH have lower IGF-I values than control patients. Further studies are needed to
confirm these potentially clinically relevant findings.
Decreased HRQoL after aSAH has been shown in several studies (Katati 2007; Kreitschmann-Andermahr 2007;
Visser-Meily  2009).  The  symptoms  of  depressed  quality  of  life  may  be  similar  to  those  caused  by  pituitary
insufficiency: fatigue, depression, anxiety, and weakness (Schneider 2007), and these symptoms may be
misinterpreted in some cases as normal neurological sequelae of aSAH. Our preliminary study shows that
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neuroendocrinological changes may be associated with morbidity, and these findings should be investigated
further in larger studies.
6.4 Limitations of the study
In this study, several different patient categories were studied. One may argue that patients admitted for elective
cardiac surgery are very different from patients with sepsis or aSAH. However, all of these patients face major
stress, inflammatory responses, and activation of the HPA axis. Disturbances in the stress-mediated
endocrinological reactions may lead to increased morbidity. Typically, all the studied patient groups are admitted
routinely to the ICU because of serious illness requiring intensive care.
In our sepsis study, cortisol sampling was not scheduled and no ACTH stimulation test was performed. Pituitary
function is affected by complex negative feedback loops and several cytokines (Marik 2008). Thus, secondary AI
may also play a role in septic patients (Prigent 2004), and this aspect requires further study. Although 125 blood
samples were collected in the sepsis study, there might have been selection bias. The cohort in the Finnsepsis
study (Karlsson 2007) was much larger, but blood samples were not available from all of the patients
Only  study III  had enough power  to  detect  possible  AI.  Our  study with  aortic  stenosis  was  had the  power  to
detect haemodynamic changes between propofol and etomidate, not differences in cortisol synthesis. Because of
this small sample size, no conclusion could be made concerning morbidity or mortality.
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7 Conclusions
1. Etomidate transiently decreases the postoperative serum cortisol concentration. Propofol is twice as likely as
etomidate to evoke hypotension when inducing anaesthesia in patients with severe aortic stenosis.
2. The behaviour of serum free and total serum cortisol was similar. Measuring free serum cortisol does not
provide any advantages over measuring total serum cortisol, and it is not better at predicting hospital mortality
in patients with severe sepsis or septic shock.
3. In the acute phase, some patients may have secondary AI. The severity of aSAH does not affect calculated free
or total serum cortisol. Measuring free serum cortisol is not helpful in determining AI in patients with aSAH.
4. Serum IGF-I concentrations are low in patients with aSAH, which may contribute to poor outcome assessed by
GOS and HRQoL.
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Appendix:
FISHER CT-SCALE
GLASGOW COMA SCALE
GLASGOW OUTCOME SCALE
HUNT & HESS SCALE
WOLRD FEDERATION OF NEUROSURGICAL SOCIETIES SCALE
ORIGINAL PUBLICATIONS I-IV
COMMENT ON STUDY III

Fisher CT-scale (Fisher 1980)
1= no blood
2= diffuse thin layer of blood, in vertical cisterns < 1mm
3= localized clot or thick layer of blood, in vertical cisterns > 1mm
4= intracerebral and/or intraventricular clot
Glasgow coma scale (Teasdale 1974)
Best Eye Response (4)
1= No eye opening.
2=Eye opening to pain.
3=Eye opening to verbal command.
4=Eyes open spontaneously.
Best Verbal Response (5)
1= No verbal response
2= Incomprehensible sounds.
3= Inappropriate words.
4= Confused
5= Orientated
Best Motor Response (6)
1= No motor response.
2= Extension to pain.
3= Flexion to pain.
4= Withdrawal from pain.
5= Localizing pain.
6= Obeys Commands.
Glascow outcome scale (Jennet 1975)
1= death
2= persistent vegetative state
3= severe disability (conscious but disabled)
4= moderate disability (disabled but independent)
5= good recovery
Hunt & Hess scale (Hunt 1968)
0= no SAH
1= asymptomatic or mild headache, mild nuchal rigidity
2= moderate to severe headache, nuchal rigidity, no neurological deficit,  expect cranial nerve palsy
3= drowniness, confusion, or mild focal deficit
4= stupor or mild to moderate hemiparesis, possible early decerebrate rigidity
5= deep coma, decerebral posturing, moribund
World Federation of Neurosurgical Societies Scale (Report…1988)
GCS Motor deficit
Grade 0 15 Absent and no SAH
1 15 Absent
2 13-14 Absent
3 13-14 Present
4 7-12 Present
5 3-6 Present or absent
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Activation of the pituitary and
adrenal axis is essential in modifying 
the stress response in critically ill
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